BioSpectrum India July 2019

www.biospectrumindia.com

Waters (India) Pvt. Ltd.

36A, 2nd Phase, Peenya Industrial Area, Bangalore - 560 058. Tel: 080-49292200-03 (3 lines)
Fax: 080-49292204, E-mail: [email protected]

Mumbai : Tel : 022-25170127, Fax : 022-25170616, E-mail : [email protected]
New Delhi : Tel : 011 - 40194100 - 4149, Fax : 011 - 40194115, E-mail: [email protected]
Kolkata : Tel : 033-23678338, Fax: 033-23678339 , E-mail: [email protected]
Hyderabad : Tel : 040-27901532, Telefax : 040-27901586, E-mail: [email protected]
Chandigarh : Tel : 0172-2623149, Telefax : 0172-2623295, E-mail: [email protected]
Ahmedabad : Tel : 079-29702903, Fax : 079-29702904, E-mail: [email protected]
Chennai : Tel : 044-22350336

Simplify the Journey™

with Integrated Solutions for Every Molecule at Any Stage

Complex drug development. Regulatory scrutiny. Clinical Phase I, II and III, Lifecycle Management and
Changing standards. Combination products. Generics, we offer solutions at any stage of development,
across all injectable formats.
Whether you are developing a biologic, pharmaceutical,
or generic product, West understands the challenges Integrating products and services into one
you face along the drug development journey because package with one partner can help you:
we live it with you.
Reduce development and supply risk
That’s why we’re introducing our Integrated Solutions Accelerate the path to market
Program – a comprehensive approach that combines Minimize total cost of ownership
West’s high-quality packaging and delivery products with Improve the patient experience
our expert analytical testing, fill-finish services, device
assembly and manufacturing, and regulatory support.
With defined packages for Prescreen and Compatibility,

Contact us today westpharma.com.

North America 1-800-345-9800 option 8 | Europe +49 (0) 2403-7960 | Asia Pacific +65 6862 3400 | India +91 40 4940 1111
West Pharmaceutical Services, Inc. 530 Herman O. West Drive | Exton, PA 19341

West and the diamond logo, By your side for a healthier world™ and Simplify the Journey™ are registered trademarks or trademarks of West Pharmaceutical Services, Inc., in

the United States and other jurisdictions.

Copyright © 2019 West Pharmaceutical Services, Inc. #11006 • 0119

4 BIO CONTENT BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

COVERSTORY 22.........................................................................................................................................................

INDIAN BIOSUPPLIERS www.biospectrumindia.com

MARKET GROWING AT 6%; TOUCHES

RS 7950 CRORE

The biosciences revenue of the Indian BioSuppliers market touched Rs 7950 COVER
crore in 2018-19 registering a growth of 6 per cent over previous year’s figure DESIGN BY:
of Rs 7500 crore. Although India is suffering the after-effects of new tax reform DOMINIX STRATEGIC
applications, a massive generic drug industry and sprouting biotech startups, DESIGN PVT. LTD.
especially in medical and drug discovery, contract research areas, will continue to
sustain growth of the market. There are over 100 leading companies in analytical
instruments space in the country who are dominating the space supported by
hundreds of distributors/ channel partners spread across the country. India still
depending on the import of all kinds of analytical instruments as it is still unable
to develop and manufacture these kind of high end precision equipment unlike in
case of vaccines, biosimilars and blood products. However Indian companies are
very much active in supplying lab consumables, kits, reagents, lab equipment, cell
culture media and lab chemicals.

25 26 27 28 29

WATERS THERMO FISHER HIMEDIA SARTORIUS SHIMADZU
INDIA SCIENTIFIC INDIA LABORATORIES STEDIM INDIA ANALYTICAL
PVT. LTD. PVT. LTD. PVT. LTD. PVT. LTD. (INDIA) PVT. LTD.

T ANIL KUMAR AMIT CHOPRA DR GANGADHAR SIBASIS DAS YOSHIYUKI FUJINO
President, India Operations Managing Director M. WARKE Sales Director (BioProcess Managing Director
CMD & Founder Solution) India, SAARC
30 31 34
32 33
WEST DSS GENETIX
PHARMACEUTICAL IMAGETECH PREMAS EPPENDORF BIOTECH ASIA
PACKAGING INDIA PVT. LTD. LIFE SCIENCES INDIA PVT. LTD.
PVT. LTD. PVT. LTD. PVT. LTD.

ALAGU SUBRAMANIAM ARVINDER DHINGRA PRAVEEN GUPTA V ARUN PRAKASH
Managing Director Managing Director Managing Director SANKARANARAYANAN CEO
Head of Sales

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com BIO CONTENT 5

35 35 36 TOPVIDEO Ritchie Ng, Head,
Deep Learning,
SAKSHAM ESCO MEDISPEC NVIDIA, US is of
TECHNOLOGIES BIOTECH (I) LTD. the view that the
PVT. LTD. PVT. LTD. growth of AI in
healthcare will be
exponential.

SAMEER MAHESHWARI SAMEER MAHESHWARI VIPUL CHATBAR
Chief – Customer Support Chief – Customer Support Chief Executive Officer

36 37 37

ANALYTICAL LAB SYSTEMS & ZEBA LAB
TECHNOLOGIES BIOTECH (I) FURNITURE
LTD. PVT. LTD. PVT. LTD.

JAY B VAKIL Scan the QR Code »
Managing Director
Dr Rajiv Desai,
SIVA PRASAD PATNAM JIJI MANIKKATH Executive VP,
Chief Executive Officer Managing Director Corporate Quality
Assurance, Lupin
38 38 39 talks about the
challenges facing
APS LIFETECH BIOLINX BHAT the Indian Pharma
INDIA BIO-TECH Industry for
PVT. LTD. INDIA PVT. LTD. developing new
products.

DR PARITOSH GIRISH NAIR DR SHAMA BHAT
SHEKHAR Director Director
Director
REGULARS Scan the QR Code »
39
BioEdit ........................................ 06 Sandra de Wild,
ANGA BIM & LAB BioMail ....................................... 08 Healthcare Expert,
ENGINEERING Policy and Regulatory News...... 10 Netherlands
DESIGNS (OPC) Company News.......................... 14 Foreign Investment
PVT. LTD. Start-up News............................ 16 Agency shares
Finance News............................. 18 details of the
YAMINI K WHO News................................. 19 healthcare sector
Managing Director World News................................ 20 in The Netherlands
Academic News......................... 42 and its potential
Science News............................ 44 interest in India.
People News.............................. 46
Supplier News............................ 48 Scan the QR Code »
BioEvent...................................... 50

6 BIO EDIT BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

Drug Prices-
Tough to Swallow

Transparency matters especially when it comes continued for four days. But as there was no complete
to medicine prices. Hence, World Health consensus what came out of the negotiations was
Organisation (WHO)’s 72nd World Health a weaker final version of the original draft. Sector
Assembly held recently deserves appreciation for experts feel that the final version, though weaker,
adopting a landmark, but controversial, resolution will boost transparency in drug prices. However, it
that intends to improve the transparency of markets is weak because it still keeps a lid on the key issue of
for medicines, vaccines and other health products. R&D cost since the resolution makes it voluntary to
The resolution urges member states to improve the disclose it and about the clinical trial results and cost.
transparency of patents of medical technologies,
including biologic drugs, vaccines, cell and gene Even after the consensus on the weaker
therapies, and diagnostics. language in the final draft, the UK tried to postpone
the review till January 2020. But that meant the
The original resolution introduced by Italy and adoption would have been delayed by one year as the
co-sponsored by 20 other countries was important resolution could have been taken for consideration
as it aimed to improve access to medicines by in next assembly in May 2020. As that attempt
bringing in transparency over cost of research & failed UK, Hungary and Germany dissociated
development of medicines and other health-related themselves from the measure. Their claims were
technologies. It urged member states to enhance that the far reaching implications of the resolution
public sharing of information on actual prices were not fully appreciated and four-month review
paid by governments and other buyers for health period since the draft resolution’s submission was
products and greater transparency on pharma insufficient.
patents, clinical trial results and other determinants
of pricing along the value chain from lab to patients. The US was in the group that wanted the R&D
cost information to be made public voluntarily.
Its ultimate objective was to help member states But, in another interesting development 40 states
to make more informed decisions while purchasing in the US have filed a lawsuit against 20 top
medicines and negotiate more affordable prices, pharmaceutical companies for conspiring to inflate
which would ultimately expand access to medicines. prices of 100 commonly used medicines. So, on a
It is interpreted as a way for governments facing global forum the US takes a stand not compelling
financial resource crunch to control their drug pharma companies to disclose their R&D cost,
spending. As such a transparency will impact the while on the other hand US states are initiating
prices of medicines thus, naturally the resolution action against pharma giants for allegedly inflating
became controversial with some countries not prices. The US should have understood that if the
favouring it as it was. These include Germany, UK, companies are compelled to disclose R&D cost
Japan, Switzerland and the US. automatically the issues like inflating prices will be
overcome.
In the pre-assembly informal negotiations on the
draft resolution these countries sought to weaken Though the language of the resolution had to
the language. The draft resolution asked member be watered down due to the pressure from member
states to make public the cost of medicines, vaccines countries, a beginning has been made. The first step
and other health related technologies, including towards transparency in prices has been taken and
the results and costs of clinical trials. But these it is noteworthy because transparency is needed to
nations opposed the point related to publication of create trust which is an important element between
R&D costs in the resolution. They wanted to leave a medicine and a patient to get cured.
it to member states to disclose this information on
voluntary basis and not to compel them to do so. Milind Kokje
Chief Editor
The pre-assembly efforts to come to consensus
[email protected]



8 BIO MAIL BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

Vol 17; Issue 06; June 2019

Acknowledgement

Congratulations BioSpectrum India. The rankings
have come out really well. I hope you have a good
response to the issue.

- K V Balasubramaniam Ph.D, Hyderabad

The BioPharma ranking issue looks good and so do
the profiles write-up.

- K. Vijay Amruth Raj, Hyderabad

Thank you so much for write-up on Novo-Nordisk.
Can you please share a high resolution image of the
Top 20 recognition of the company done on your
cover page?

- Madhuri Jacob, Bengaluru

Thank you so much for the feature on Bharat Biotech
in the BioPharma ranking issue. Wish the magazine
had more categories so that companies and their
respective biz could be featured in right perspective.

- Muralidharan, Hyderabad

Vol 17; Issue 07; July 2019 MM Activ Sci-Tech Communications

Publisher & Managing Editor: South Region New Delhi INTERNATIONAL
Ravindra Boratkar Alok Srivastava Kalyani Sharma
National Business Head- Media Coordinator Singapore
Editorial: Ad Sales & Marketing 103-104, Rohit House 3, MM Activ Singapore Pte. Ltd.
Chief Editor: Milind Kokje ‘NITON, Block ‘C’, I Floor, No.11/6, Tolstoy Marg, Connaught Place, Saradha Mani
[email protected] Palace Road, Bangalore-560 052 New Delhi - 110 001 Manager Admin &
Mobile: +91-9845128747 Tel. No: +91 11 4354 2737 Sales Support
Advisor - Content: Vijay Thombre Tel.: +91-80-41131912/13 [email protected] #08-08, High Street Centre,
[email protected] 1 North Bridge Road,
General Manager Content Creation Singapore - 179094
and Coordination: Narayan Kulkarni Mumbai Pune Tel: +65-63369142
Content Team: Ankit Kankar Fax:+65-63369145
Bengaluru: Dr Manbeena Chawla Manager- Product & Ankit Kankar [email protected]
New Delhi: Kalyani Sharma Manager- Product &
Mumbai: Prapti Shah Marketing Communication Marketing Communication USA
Pune: Dr Sonali Wankhade 156, Kaliandas Udyog Bhavan, Ashirwad, 36/A/2, S.No. 270, Pallod Media Representative:
Singapore: Hithaishi C. Bhaskar Babasaheb Woralikar Marg, Farms, Baner Road, Pune- 411045 Christen Pickens
Mumbai - 400 025 Mobile: +91-9579069369 Senior Connections Planner
Social Media Editor: Ankit Kankar Mobile: +91-9579069369 [email protected] Havas Media
[email protected] [email protected] 200 Hudson,
New York, USA, 10013
CFO & Special Correspondent: Nagpur Tel: +1 646 5875000
Manasee Kurlekar Manisha Boratkar [email protected]
402, Govind Apartments, Shankar Nagar Square,
Production & Design: Nagpur - 440 010. Tel. +91-712-2555 249 Europe
MM Activ Sci-Tech Communications Media Representative:
Anil Walunj Printed and published by Sandup Sherpa
Ravindra Boratkar on behalf of MM Activ Sci-Tech Communications Pvt Ltd Associate Digital Investment
Product & Marketing Havas Media
Ankit Kankar Printed at Spectrum Offset, D 2/4 Satyam Estate, Behind CDSS, Tel: +1347-482-0278
[email protected] Pandurang Colony, Erandwane, Pune - 411004. Tel : +91 20 2543 6556 [email protected]
TIN No: 09565712431
Content Creation and Published from Ashirwad, 36/A/2, S.No. 270, Pallod Farms,
Coordination: Near Bank of Baroda, Baner Road, Pune- 411045.Tel. No: +91 20 2729 1769
Dr Manbeena Chawla Website: www.biospectrumindia.com
[email protected]

Circulation, Subscription and
Media Enquiry:
Asmita Thakar
[email protected]

Genei Laboratories joins hands with Avantor / VWR

Diagnostics Kits & Reagents

PCR & qPCR Kits for Quality reagents, Accurate &
Molecular Diagnostics consistent research kits
- Human Application
- Veterinary Application - Nucleic Acid Purification
- Plant Application kits

Scientific Services - Protein Purification &
Estimation Kits
- Genomics Services
- Proteomics Services - Reagents & Buffers
- Antibody Production &
Educational Kits
Conjugation Services
Certified Skill Development
Partner
- Self-Contained Teaching

Kits
- Training & Workshops

We are pleased to announce that Genei Laboratories has appointed Avantor/
VWR to promote and expand the sales and distribution of Genei Products
within India on exclusive basis.

Avantor is a global manufacturer and distributor Genei Laboratories manufactures an array of high
of high quality products, services and solutions quality reagents pertaining to molecular biology
to professionals in life sciences and advanced and protein science along with kits for teaching and
technologies industries. As our channel brand, VWR Diagnostics. Genei also provides custom research
offers an integrated, seamless purchasing experience services and delivers top notch products from other
that is optimized for the way our global customers do manufactures both international and domestic.
business.

AVANTORSCIENCES.COM

INDIA HEADQUARTERS
Avantor Performance Materials India Limited
17th Floor, Building No. 5, Tower C,
DLF Cyber City
Phase - III, Gurgaon - 122002, Haryana
t +91 124 4656700
f +91 124 4656799

10 POLICY AND REGULATORY NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

Health Ministry bans
electronic smoking devices

Himachal The health ministry has proposed to 10A of the legislation. In a white
government classify alternative smoking devices paper released in May 2019, the
to explore such as Electronic Nicotine Delivery Indian Council of Medical Research
Ayurgenomics Systems (ENDS), as "drugs" under (ICMR) said e-cigarettes adversely
the Drugs and Cosmetics Act, in affects the cardiovascular system,
A Memorandum of a bid to ban their manufacture, impairs respiratory immune cell
Understanding (MoU) has sale, distribution and import. function and airways in a way
been signed between the The proposal has been approved similar to cigarette smoking and is
state of Himachal Pradesh by the Drug Technical Advisory responsible for severe respiratory
and Frankfurt Innovation Board (DTAB), the government's diseases.
Zentrum (FIZ) in the top advisory body on technical
fields of Ayurgenomics matters related to medicines in the
(Ayurveda and Genomics), country. Indian drug regulator, the
precision medicine and Central Drugs Standard Control
precision agriculture. It Organisation (CDSCO), under
was signed in the presence the health ministry has proposed
of Chief Minister Jai that the manufacture, sale and
Ram Thakur, who was distribution of ENDS, including
on a visit to Germany e-cigarettes and similar products,
and Netherland to attract should be prohibited under Section
the investors to invest in 26A of the Drugs and Cosmetics
the North-Indian state. Act, 1940, while their import
According to FIZ CEO Dr should be outlawed under Section
Christian Garbe, a cross-
learning programme is Cabinet approves Indian
required to have a better Medical Council Bill 2019
understanding of the local
requirements as well as Reforms in the field of Medical education so as to give a push to the goal of
how Ayurgenomics can
play a pivotal role in the a quality health coverage to the citizens of India has been one of the major
healthcare and wellness
sectors. pillars of the NDA Government led by Prime Minister Narendra Modi.

Keeping the spirit alive and to fulfil yet another promise of the Government,

the Union Cabinet, chaired by the Prime Minister Narendra Modi, has

approved the Indian Medical Council (Amendment) Bill, 2019 to replace

the Indian Medical Council

(Amendment) Second

Ordinance, 2019 through an

Act of Parliament. The Bill will

be introduced in the ensuing

session of the Parliament. The

move will ensure transparency,

accountability and quality in

the governance of medical

education in the country.

The New Bill provides for

supersession of MCI for a

period of two years w.e.f. September 26, 2018. During this period, the Board

of Governors shall exercise the powers and functions of MCI as assigned

under the IMC Act, 1956. The number of members in the Board of Governors

will be increased from existing 7 to 12.



12 POLICY AND REGULATORY NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

Agreement worth $287M to India, Kyrgyzstan
improve healthcare in Tamil Nadu to strengthen
healthcare
The Government of India, Government of Tamil Nadu (GoTN) and
the World Bank recently signed a $287 million loan agreement The Union Cabinet, chaired by the
for the Tamil Nadu Health System Reform Programme. The Prime Minister Narendra Modi,
programme aims to improve the quality of health care, reduce has approved a Memorandum
the burden of non-communicable diseases (NCDs), and fill equity of Collaboration (MoC) between
gaps in reproductive and child health services in Tamil Nadu. The India and Kyrgyzstan for
Tamil Nadu Health System Reform Programme will support the collaborative research work
state government to develop clinical protocols and guidelines; to on High Altitude Biology and
achieve national accreditation for primary, secondary, and tertiary- Medicine and aiming at further
level health facilities in the public sector; to strengthen physicians, development and strengthening
nurses and paramedics through continuous medical education; of mutual relationships in
and to strengthen the feedback loop between citizens and the state science and medicine, especially
by making quality and other data accessible to the public. The in high altitude biology and
agreement for the Project was signed by Sameer Kumar Khare, medicine. The MoC will help in
Additional Secretary, Department of Economic Affairs, Ministry understanding the physical and
of Finance, on behalf of the Government of India, Beela Rajesh, mental picture of soldier system
Secretary, Health and Family Welfare Department, on behalf of at high altitude and mitigate the
the Government of Tamil Nadu and Hisham Abdo, Acting Country high altitude related maladies by
Director, World Bank India, on behalf of the World Bank. using yoga practice, herbals and
neutraceuticals in Indian and
Kyrgyz solders/population. The
Cabinet has also approved the
proposal of the Ministry of Health
& Family Welfare for signing a
Memorandum of Understanding
(MoU) between the Ministry
of Health & Family Welfare of
the Republic of India and the
Ministry of Health of the Kyrgyz
Republic in the field of Health.

NHA, QCI to fast track digital certification for hospitals

National Health Authority at least 7,000 empanelled hospitals put in place a simple, swift,
(NHA) and Quality Council by December 2021 to build a transparent and paperless
of India (QCI) have network of quality healthcare mechanism to encourage
signed a Memorandum of providers. The MoU seeks to the hospitals to apply for
Understanding (MoU) for certification. Following the
launching a joint initiative existing policy of incentivising
of digital certification for the accredited hospitals, NHA
Ayushman Bharat - Pradhan also plans to incentivise
Mantri Jan Arogya Yojana the certified hospitals with
(AB-PMJAY) empanelled higher reimbursement rates
hospitals. The initiative so that more hospitals apply
will help the hospitals to for certification. There will be
get fast-track certification while three levels of AB-PMJAY quality
enhancing healthcare services. certifications: Bronze, Silver and
The partnership aims to create a Gold with Gold being the highest
process to facilitate certification of level under this initiative.



14 COMPANY NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

Abbott launches advanced mapping catheter in India

Abbott has announced the launch of its HD grid It offers physicians a unique grid configuration that
mapping catheter, which is sensor enabled in India. captures this critical information and enables the
This product received USFDA clearance last year in creation of high-density maps of cardiac tissue to
May. The catheter employs a new design that allows support optimal treatment for patients. With this grid
physicians to see things differently, capturing and mapping catheter, for the first-time physicians can
analyzing data in a novel manner to create highly see electrical signals that they may have missed using
detailed maps of the heart that better differentiate standard mapping catheters.
healthy from unhealthy tissue. The new mapping
catheter builds upon Abbott’s innovative products
designed to improve how physicians perform cardiac
ablation procedures, including cardiac mapping
systems and treatment catheters. The new catheter
from Abbott is designed to capture information —
such as the direction and speed of cardiac signals
— often missed with traditional mapping catheters.

Meril receives AstraZeneca opens
CE approval new clinical research unit
for Myval
Transcatheter Global science-led biopharmaceutical company, AstraZeneca
Heart Valve has officially announced the expansion of its clinical research
operations in India with the launch of a new dedicated unit
Meril Life Sciences has become the in Bengaluru. This new Development Operations Centre will
first Indian company to market and cement AstraZeneca’s position as a leading initiator of clinical
distribute its indigenously designed research in the country. AstraZeneca is among the top 3 initiators
and patented TAVR technology, of clinical studies among foreign pharmaceutical companies in
Myval-THV system, to European India in the past three years, according to publicly available
data. The new centre is located at Manyata Business Park in
Union and other Bengaluru alongside the India marketing and manufacturing
countries. The headquarters. The Development Operations Centre will employ
CE certification over 30 clinical research experts that handle over 20 studies in
is a conformity 150 sites across India. This expansion will focus on managing
mark indicating studies in India to not only support the global clinical drug
the product to be development, but also the local business with clinical data and
compliant with the evidence. The unit will support development of AstraZeneca’s
European Union (EU) medicines, hosting clinical trial experts focused on the
health standards. company’s core therapeutic areas: oncology, cardiovascular,
The CE certification renal and metabolism, as well as respiratory.
would enable Myval-
THV to reach over
60 countries in Europe and outside of
India which accept CE mark document
for their own regulatory approvals.
TAVR is an established treatment
modality for patients who are at a risk
or unwilling to undergo open heart
valve replacement surgery. TAVR is
a minimally invasive procedure that
repairs the aortic heart valve without
removing the old, damaged valve.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com 15

Advertorial

Mayo Clinic ranked
No.1 hospital in the U.S.

Mayo Clinic in Rochester, Mayo Clinic ranked No. 2 in four to eliminate any financial pressure from
Minnesota, was again named the specialties — Cardiology and Heart patient care decisions Mayo Clinic’s
best hospital in the United States in Surgery, Orthopedics, Pulmonology experts work across specialties
U.S. News & World Report’s 2018- and Urology (two-way tie). It ranked to provide comprehensive and
19 Best Hospitals. Mayo Clinic also No. 3 in Cancer. coordinated care for patients.
ranked No. 1 in more specialties than
any other hospital in the country. Specialties are measured for “Our top ranking is only possible
various factors, including mortality because of our talented staff,” Dr.
Mayo Clinic has always ranked at index, patient safety, nurse Farrugia said. “Mayo Clinic’s emphasis
or near the top of the annual “Best staffing and Magnet status (the on collaboration and teamwork allows
Hospitals Honor Roll.” Mayo Clinic gold standard in nursing), patient us to bring the full spectrum of our
in Arizona, Florida and Minnesota services, technology and reputation. knowledge and expertise together to
was also ranked No. 1 within those Mayo Clinic staff work to deliver focus on the individual needs of each
states. the highest standards of care and patient.”
transform scientific discoveries into
Mayo Clinic is part of a select clinical advances that help people Mayo Clinic is a global destination
group of hospitals recognized on everywhere. for patients with serious and complex
the “Best Hospitals Honor Roll” for conditions. More than 1.3 million
“breadth of excellence,” according “We are humbled and honored by people from about 140 countries
to U.S. News & World Report. The our ranking with U.S. News & World turn to Mayo Clinic for diagnosis and
honor roll consists of 20 hospitals Report,” said Gianrico Farrugia, M.D., treatment each year.
with the highest combined overall president and CEO, Mayo Clinic. “We
scores in 16 medical and surgical have continuously refined our system “Our primary value is that the
specialties. of care for more than 150 years. We needs of the patient comes first. We
are always working to deliver accurate take that value and we embed it in
Mayo Clinic ranks first, second or answers as quickly as possible and everything we do,” Dr. Farrugia said.
third in 11 specialties, including No. 1 ensure the best outcomes for our
rankings in six specialties: patients.” Many outside agencies rate
quality in health care. Mayo Clinic is
 Diabetes and Endocrinology Mayo Clinic’s commitment to the only health care organization that
 Gastroenterology and quality dates back more than 150 consistently ranks among the top
 Gastrointestinal Surgery years to when the Mayo brothers providers nationwide regardless of the
 Geriatrics invented the team-based approach quality measure used.
 Gynecology to medicine – an approach that
 Nephrology continuously evolves and improves.  For more information or to make an
 Neurology and Neurosurgery Mayo Clinic’s physicians are salaried appointment, visit www.mayoclinic.
org/international

16 START UP NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

CoWrks Narayana Health, MSMF to support
Foundry health-tech startups globally
launches
healthcare Narayana Health along with As part of the partnership Pixel
accelerator Mazumdar Shaw Medical
programme Foundation (MSMF) has Display will undergo rigorous
announced that they have
Earlier this year, the CoWrks signed a memorandum of product and market validation
Foundry partnered with the Yale understanding (MoU) with THE
Institute for Global Health (YIGH), GAIN, a Global accelerator and at the Narayana Health City.
supported by RMZ Foundation, Pixel Display, a startup company
to announce the collaborative based out of South Korea. Pixel Display is an innovative
Sustainable Health Initiative The partnership will witness
(SHI). The SHI is a 24-week Narayana Health and MSMF company from South Korea
long interdisciplinary business providing guidance and offering
accelerator programme for young a conducive environment for that develops AI based mobile
and early stage startups building healthcare technology startups
innovative solutions in healthcare. to validate their innovations. pediatric ophthalmological
The SHI parogramme has been
designed to power ‘Innovation’ examination solution. It brings
for long-term social, health and
environmental impact in emerging an innovative technology called
economies. With the ecosystem
ripe for innovation, healthcare 'KIZOPTER'. This technology
companies in India are effectively
poised to impact billions in the helps in accurate and rapid eye
country as well as globally. As part
of this programme, each startup examination in children without
will receive up to $70,000 in seed
funding, mentorship from Yale’s any additional hardware other
faculty and alumni, as well as
benefits from a network of Indian than the mobile.
industry experts. In addition, the
programme includes structured NATHEALTH, Well Tech join
sessions to help startups evolve into hands to promote health startups
a sustainable and scalable business
model, refine their go-to-market Apex healthcare industry body NATHEALTH has announced its
strategy and build a global network. collaboration with global health-focused innovation platform Well
Technologies Ltd ( Well Tech) to support healthcare startups
with access to capital & market, industry partnership, mentorship
and technology development
assistance. NATHEALTH, in
association with Well Tech, plans
to infuse seed investment of
upto $ 1.5 million. NATHEALTH
and Well Tech have signed a
Memorandum of Understanding
(MoU) for this collaboration and
under the agreement, these two
healthcare entities agreed for a
joint initiative to scale up and
serve millions of patients and customers. The joint initiative will
provide Health start-ups with access to capital, industry partnerships,
and product & technology support along with helping them scale to
new markets. Together, the two organizations, and their partners and
members, will support startups to scale up across India and globally.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com START UP NEWS 17

Omnicuris pools Healthtech startup
preventive cardiology Pristyn Care raises $4M
with pre-diabetes
Healthcare delivery startup Pristyn Care has raised $
Online CME platform Omnicuris is aiming to 4 million in Series A round of funding from Sequoia
extend its reach to 2.5 lakh doctors to achieve India. The startup will use the funds to improve
a 150 per cent hike over its current user base its medical capabilities, invest in technology and
by the end of FY 2019. The Bengaluru based expand its medical team. Pristyn Care offers patients
healthcare startup is also planning to further affordable advanced surgical care through innovative
diversify its content base across specialities surgical techniques and recovery measures. It claims
to be able to offer online tutorials to doctors to have facilitated over 2000 surgeries till now. It
across the country. The startup has signed is currently operational in 20 clinics across Delhi,
MoUs with government bodies that will Bengaluru and Hyderabad, and plans to expand its
enable physicians in Tier II and Tier III cities clinic network to 50 by December 2019.
to access its modules. Omnicuris intends to
establish further relationships with more
state governments while delving further
into the content space and expanding into
specialties where it is currently not present.

Focus on Science Get Quotes For Laboratories
Leave the Quotations to Us on
Free of Cost
Request a Quote on WhatsApp in 3 Steps: Regular Updates
1 Add +91-80-25043084 to your Contacts
Any Brand
2 Tell us what your lab needs on WhatsApp +91-80-25043084 Product Analysis

3 We get the quotes; you select the products Add To For Suppliers
CONTACTS
New Customers
CloudKrate also provides: Scan Now Increased Sales
Pay As You Win
Lab Inventory Manager | New Lab Setup | Cost Analytics Digital Sales Tool

CloudKrate was incubated and funded by IIM Bangalore
Contact Us:
Phone: +91-9820071580 Mail: [email protected]

18 FINANCE NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

India Alternatives invests $8M in Brinton Pharma

India Alternatives Investment respiratory segments. paediatric formulations. Through
Advisors has invested Established in 2013, Brinton a specialized and dedicated field
up to $8 million Pharmaceuticals is a speciality- force of over 500 personnel, the
for a significant focused pharmaceuticals company’s products are marketed
minority stake in company offering a range of in India and in 12 countries across
Pune based Brinton branded dermatology and emerging markets. According to
Pharmaceuticals the company, this investment
Limited. Among the will enhance its capabilities in
fastest growing companies formulations and Research &
in the Indian pharmaceutical Development for niche areas of
market, Brinton is focused dermatology and cosmetology
on dermatology and has and support expansion of the
recently expanded into the company’s footprint within India
paediatric dermatology & as well as globally.

Dr. Reddy’s sells 2 neuro Japanese firm
products to Upsher-Smith
announces investment
Dr. Reddy’s Laboratories has announced that it has
entered into a definitive asset purchase agreement with plan with C-CAMP
Upsher-Smith Laboratories, LLC (Upsher-Smith),
pursuant to which Dr. Reddy’s would sell its US and The Centre for Cellular and Molecular Platforms
select territory rights for ZEMBRACE SYMTOUCH (C-CAMP), India’s premier bio-innovation hub
(sumatriptan injection) 3 mg and TOSYMRATM recently signed a Letter of Intent (LoI) with
(sumatriptan nasal spray) 10 mg, (formerly referred Beyond Next Ventures (BNV), one of the leading
to as “DFN-02”), which are commercialized through independent accelerators in Japan dedicated to
its wholly owned subsidiary, Promius Pharma, LLC. incubation investment in technology startups. The
Under the agreement, Dr. Reddy’s will receive $70 broad aim of this collaboration is to encourage and
million as upfront consideration, $40.5 million promote the best deep science innovations in the
in near term milestones and additional financial field of Life Sciences and Biotechnology in India.
considerations including, existing contractual The two organizations intend to create the C-CAMP
obligation and inventory. Subsequently, Dr. Reddy’s – BNV Innovation Hub (CBIH) which will largely
will receive sales based royalties on a quarterly basis. focus on facilitating Japanese investment of up to
The closing of the transaction is subject to various $5 million in Indian startups working on exciting
customary closing conditions including antitrust technologies in the Life Sciences and Biotech
review under Hart-Scott-Rodino Act. domain. This hub also aims to support startups
in both the regions through exchange of human
resources and technologies and through other
facilitation programs and events to connect skilled
talent, entrepreneurs and other stakeholders in
both regions.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com WHO NEWS 19

WHO urges WHO highlights new
countries to fight study on HIV transmission
tobacco epidemic
A large clinical research study conducted in four
The World Health Organisation (WHO) is urging African countries found no significant difference in
countries to fight the tobacco epidemic through risk of HIV infection among women using one of three
full implementation of the WHO Framework highly effective, reversible contraceptive methods.
Convention on Tobacco Control (WHO FCTC) Published in the Lancet, the study showed that each
and enforcing effective tobacco control actions, method had high levels of safety and effectiveness in
including WHO’s recommended “MPOWER” preventing pregnancy, with all methods well-accepted
policy measures, for example by reducing demand by the women using them. The three methods
for tobacco through taxation, creating smoke-free investigated in the trial known as the Evidence for
places and cessation support. The organization Contraceptive Options and HIV Outcomes (ECHO)
also encourages parents and community leaders study were: DMPA - intramuscular (DMPA-IM), a
to take steps to safeguard the health of their three monthly, progestogen-only, reversible injectable
families and communities by informing them of contraceptive; Levonorgestrel implant, a progestogen-
and protecting them from the harms caused by only implant inserted under the skin in the upper arm
tobacco. In 2017, tobacco killed 3.3 million users that can be used for up to five years; and a copper-
and people exposed to second-hand smoke from bearing IUD, a device inserted into the uterus that can
lung-related conditions, including 1.5 million be used for up to 10-12 years. According to WHO, the
people dying from chronic respiratory diseases, study highlights the need to step up HIV prevention
1.2 million deaths from cancer (tracheal, efforts in these high-burden countries - particularly
bronchus and lung) and 600 000 deaths from for young women.
respiratory infections and tuberculosis.

New collaboration between WHO and France

Emmanuel Macron, President hub will feature high-tech learning
of the French Republic and Dr environments, a world-class
Tedros Adhanom Ghebreyesus, health emergencies simulation
World Health Organisation centre and collaboration spaces
(WHO) Director-General have for learning co-design, research
signed a Declaration of Intent to and innovation. The Academy
establish the WHO Academy that will bring together adult learning
will revolutionize lifelong learning science, behavioural science and
in health. The Academy aims to cutting-edge learning technologies
reach millions of people with such as artificial intelligence and
innovative learning via a state-of- virtual reality with WHO’s norms,
the-art digital learning experience standards and evidence to deliver
platform at a campus in Lyon high-impact accredited and
and embedded in the six WHO tailored multilingual learning to
regions. The WHO Academy Lyon meet diverse needs.

20 WORLD NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

Maldives offers Sri Lanka gets first AI
new health based healthcare chatbot
insurance services
eChannelling, the largest Doctor Channeling Network in
Maldivian Health Insurance Company, Sri Lanka, has launched the Chatbot for the first time in
Aasandha, has signed a Memorandum Sri Lanka’s healthcare industry. To provide this convenient
of Understanding (MoU) with Ninewells method to its customers, eChannelling has joined hands
Hospital in Sri Lanka in order to provide with Autochatic, creators of the world's only no-coding,
health insurance services to the Maldivian context-aware multilingual Chatbot building platform.
community residing in Sri Lanka. Autochatic is headquartered in Paris and has operations
Ninewells Hospital is Sri Lanka’s leading in Europe, Singapore, New Zealand and Sri Lanka.
women and childcare hospital and offers eChannelling Chabot is the very first artificial intelligence
a range of specialized services including (AI) based channeling bot in the country leveraging on
obstetrics, gynaecology, paediatrics and Facebook’s messenger platform. Through this, patients can
fertility. Previously, the Aasandha scheme channel a doctor and complete the transaction, including
offered universal health insurance to making payments. The Chabot is yet another state-of-the-
Maldivians for treatment abroad in cases art digital initiative by eChannelling, a 24X7 virtual agent
where medical care was not available that provides a human-like experience to find information
within the Maldives. In April, Aasandha such as doctors’ availability, doctors’ sessions etc. It also
introduced the Merana scheme under provides real-time updates of appointment sessions.
which Maldivians living in Sri Lanka are
eligible for Medical Insurance Services.
The new Merana scheme covers a wide
range of services including those covered
by the Aasandha scheme and additional
services such as deliveries, gynecology
services and childcare.

Pakistan to organise training on clinical governance

A Memorandum of Understanding be used for training and orienting management. PIM will offer
(MoU) has been signed between the leaders in healthcare quality various diploma programmes
Sindh Healthcare Commission developed by SHC in the field of
(SHC) and Pakistan Institute of Healthcare. To train doctors and
Management (PIM) to establish a community health workers on
relationship to promote Clinical infection control, a tripartite MoU
Governance in Healthcare has been signed between SHC,
management through collaborative Health Department and Medical
research, trainings, seminars and Microbiology and Infectious
conferences. The Service Delivery Diseases Society of Pakistan
Standards developed by SHC will (MMIDSP).

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com WORLD NEWS 21

IBM, KPMG, Merck &
Walmart to evaluate
use of blockchain in Pharma

IBM, KPMG, Merck and as they are distributed within the
Walmart have announced
that the companies have been United States. Each company
selected by the United States
Food and Drug Administration brings unique expertise to the PATH, Quansys
(FDA) to be included in a Bio develop
programme in support of the project, which will create a new diagnostic
U.S. Drug Supply Chain Security tool for malaria
Act (DSCSA) that addresses shared permissioned blockchain
requirements to identify, track
and trace prescription medicines network that allows real-time
and vaccines distributed
within the United States. The monitoring of products. The
programme is intended to assist
drug supply chain stakeholders, proposed network is intended
including FDA, in developing
the electronic, interoperable to help reduce the time needed
system that will identify and
trace certain prescription drugs to track and trace inventory;

allow timely retrieval of reliable PATH and Quansys Biosciences,

distribution information; Inc. have announced the launch

increase accuracy of data shared of a new diagnostic tool designed

among network members; and to help researchers develop

help determine the integrity more sensitive and reliable

of products in the distribution malaria rapid diagnostic tests

chain, including whether (RDTs) and to support public

products are kept at the correct health surveillance. The Q-Plex

temperature. Human Malaria Array (5-Plex)

is a quantitative immunoassay

that simultaneously measures

multiple malaria antigens.

Many current RDTs function

by detecting the histidine

rich protein 2 (HRP2) to

identify P. falciparum malaria

and the Plasmodium lactate

dehydrogenase (pLDH)

antigen to diagnose P. vivax

malaria and all other human

malaria species. As RDTs

improve in quality, there is a

Bayer to bring NGS based need to understand how these
companion diagnostics in oncology
antigens behave in a malaria
Bayer AG and Foundation Medicine, Inc. have announced a
global collaboration for the development and commercialization exposed population so that the
of NGS-based companion diagnostics. This agreement allows for
collaboration across multiple oncology drug candidates and approved performance of these RDTs
therapies developed by Bayer and covers Foundation Medicine’s full
portfolio of tests, including FoundationOneCDx. The first project will and their potential to support
be to develop a companion diagnostic for larotrectinib, the first and
only TRK inhibitor approved in the U.S. for patients with TRK fusion malaria elimination can be fully
cancer across all solid tumors. NGS-based companion diagnostic
tests aim to unlock molecular information from each patient’s assessed. With a single sample,
tumor genome to guide treatment decisions for cancer therapies.
FoundationOneCDx is the first FDA-approved broad companion the Q-Plex Human Malaria
diagnostic for all solid tumors.
Array can measure HRP2 and

pLDH at low concentrations, as

well as quantify P. vivax- and

P. falciparum-specific LDH

epitopes to distinguish between

malaria species and C-reactive

protein (CRP) as an indicator of

inflammation.

22 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

INDIAN BIOSUPPLIERS

MARKET GROWING AT 6%; TOUCHES

RS 7950 CRORE
The biosciences revenue of the Indian
BioSuppliers market touched Rs 7950 crore and private sectors comprising of academia, pharma
in 2018-19 registering a growth of 6 per cent and biotech companies, contract/ clinical research
over previous year’s figure of Rs 7500 crore. organisations (CROs) etc.
Although India is suffering the after-effects
of new tax reform applications, a massive generic drug Sales in academia space originated from the vast
industry and sprouting biotech startups, especially in number of universities and research institutes as well as
medical and drug discovery, contract research areas, will the continued investments in scientific infrastructure,
continue to sustain growth of the market. The overall is the larger market for life sciences segment.
analytical instruments market in India is over Rs 15000 Pharmaceutical and biotech companies occupy the
crore growing at 4 per cent. Basic research, pharma and next largest market slices, and it so happens that
biotech, contract and clinical research are contributing this is also the space that drives much of the market
over 50 per cent of the total market in the country. growth for the life sciences instrumentation industry.
As top drug companies continue to feed their pipeline
Mumbai based Thermo Fisher Scientific India Pvt with novel products, they constantly equip their R&D
Ltd is a leading analytical instruments company in and QC laboratories with new instruments, as well as
India with sales revenue of Rs 2100 crore in 2018-19 and provide a substantial installation based for spending
team strength of over 2000 and 400 channel partners. on aftermarket products and service. These companies
But its sales revenue from biosciences space stands also routinely outsource their work to CROs, fuelling
at Rs 840 crore. Bengaluru based Waters India Pvt Ltd the demand from this segment as well. The reliance
with total sales revenue of Rs 1300 crore regains No 1 of hospitals and clinical laboratories on life science
position in bio suppliers market (biosciences area with instruments leads them to capture one-tenth of the
sales revenue of Rs 1200 crore). Mumbai based HiMedia market.
Laboratories stands third in the table with biosciences
sales revenue of Rs 650 crore in 2018-19. Some of the leading distributors in the country
include Spinco Biotech, Lab India, Imperial Life
There are over 100 leading companies in analytical Sciences, DSS Imagetech, Genetix Biotech Asia,
instruments space who are dominating the space Labmate Asia, Premas Life Sciences and others.
supported by hundreds of distributors/ channel
partners spread across the country. All the top 50 According to indiamart.com, as on June 24, 2019
global analytical instruments companies namely there are 2488 Laboratory Instruments available
Thermo Fisher, Agilent, Danaher, Illumina, Merck, from different companies in different price ranges.
Waters, Shimadzu, PerkinElmer, Bruker, Mettler Toledo, Similarly 302 Analytical Instruments, 121 HPLC systems,
Becton Dickinson, QIAGEN, GE, ZEISS, Bio-Rad, Hitachi, 628 Spectrometers, 101 Cell culture media, 833
JEOL, AMETEK, Roche, Sartorius Eppendorf, Olympus, Laboratory reagents, 3580 Laboratory chemicals, 167
Spectris, Nikon, Tecan, Rigaku , Promega, Anton Paar, Laboratory consumables, 6706 Laboratory Equipment,
HORIBA, Oxford Instruments, Metrohm, Avantor, 942 Centrifuge machine and 150 Fermenters are
Luminex, Dassault Systèmes (BIOVIA), FOSS, JASCO, available for use by different sections of research and
Xylem, ITW, Takara Bio, Roper, MTS, Endress+Hauser, development.
TOSOH, LECO, Hanna Instruments, Zwick Roell, Parker
Hannifin, Teledyne and LabWare, have a direct or India still depending on the import of all kinds
indirect presence in the country. of analytical instruments is unable to develop
and manufacture these kind of high end precision
Besides there are hundreds of small and medium equipment unlike in case of vaccines, biosimilars
size companies who have been in the business in and blood products. However Indian companies are
India catering to the different requirements in public very much active in supplying lab consumables, kits,
reagents, lab equipment, cell culture media and lab
chemicals.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 23

Waters India Pvt Ltd Bengaluru based Waters Top 15
regains India Pvt Ltd leads the Bio BioSupplier
Suppliers market (Biosciences Companies
No 1 position area with sales revenue of Rs are
1200 crore in 2018-19 followed growing at
in Bio Suppliers market by Mumbai based Thermo a rate over
(Biosciences area) Fisher Scientific India with 20%
Biosciences sales revenue
of Rs 840 crore (second)
and Mumbai based HiMedia
Laboratories with sales
revenue of Rs 650 crore (third)
respectively.

BioSpectrum Top 20 BioSupplier Companies 2019*

Sr. Company Revenue Revenue % Category Location Region
No. in 2018-19 in 2017-18 growth
(in crore) (in crore) South
West
1 Waters India Pvt Ltd 1200.00 1150.00 4 Principal Bangalore West
2 Thermo Fisher Scientific India Pvt. Ltd. South
3 HiMedia Laboratories Pvt. Limited 840.00 NA NA Principal Mumbai West
4 Sartorius Stedim India Pvt Ltd South
5 Shimadzu Analytical (India) Pvt Ltd 650.00 490.00 33 Principal Mumbai North
6 West Pharmaceutical Packaging India Pvt. Ltd., North
7 DSS Imagetech Pvt. Ltd. 500.00 435.00 15 Principal Bangalore South
8 Premas Life Sciences Pvt. Ltd. North
9 Eppendorf India Private Limited 467.50 459.70 2 Principal Mumbai West
10 Genetix Biotech Asia Pvt Limited West
11 Saksham Technologies Private Limited 370.00 322.00 15 Principal Hyderabad West
12 Esco Biotech Private Limited West
13 Medispec India Ltd 204.59 210.35 -3 Distributor New Delhi West
14 Analytical Technologies Limited South
15 Lab Systems & Biotech (I) Pvt. Ltd 184.00 145.00 30 Distributor New Delhi West
16 Zeba Lab Furniture Private Limited West
17 APS Lifetech 145.00 131.00 11 Principal Chennai South
18 Biolinx India Pvt. Ltd. South
19 Bhat Bio-Tech India Private Limited 101.00 91.00 11 Distributor New Delhi
20 Anga Bim & Lab Engineering Designs (Opc) Pvt. Ltd
61.96 53.26 16 Distributor Mumbai

51.89 47.69 9 Distributor Mumbai

37.50 28.00 34 Distributor Mumbai

28.00 21.00 33 Principal Vadodara

22.40 13.00 72 Distributor Mumbai

13.00 10.00 30 Principal Ernakulam

7.80 6.20 26 Principal Pune

7.50 7.00 7 Distributor Thane

0.59 NA NA Principal Bangalore

0.20 0.05 300 Principal Bangalore

* We have not covered some of the leading Principal companies and Distributors as they are unable to participate in the BioSpectrum Bio Suppliers Survey 2019

Top 3 BioSupplier Top 10 BioSupplier Top 20 BioSupplier

companies contribute companies contribute companies contribute

35%to of the total 60%to of the total 65%to of the total
BioSupplier market BioSupplier market
BioSupplier market

24 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

BioSpectrum Top BioSupplier Companies 2019 (Principal)

Sr. Company Revenue Revenue % Category Location Region
No in 2018-19 in 2017-18 growth
(in crore) (in crore)

1 Waters India Pvt Ltd 1200.00 1150.00 4 Principal Bangalore South

2 Thermo Fisher Scientific India Pvt. Ltd. 840.00 NA Principal Mumbai West

3 HiMedia Laboratories Pvt. Ltd. 650.00 490.00 33 Principal Mumbai West

4 Sartorius Stedim India Pvt. Ltd. 500.00 435.00 15 Principal Bangalore South

5 Shimadzu Analytical (India) Pvt. Ltd. 467.50 459.70 2 Principal Mumbai West

6 West Pharmaceutical Packaging India Pvt. Ltd. 370.00 322.00 15 Principal Hyderabad South

7 Eppendorf India Pvt. Ltd. 145.00 131.00 11 Principal Chennai South

8 Analytical Technologies Ltd. 28.00 21.00 33 Principal Vadodara West

9 Zeba Lab Furniture Pvt. Ltd. 13.00 10.00 30 Principal Ernakulam South

10 APS Lifetech 7.80 6.20 26 Principal Pune West

11 Bhat Bio-Tech India Pvt. Ltd. 0.59 NA Principal Bangalore South

12 Anga Bim & Lab Engineering Designs (Opc) Pvt. Ltd. 0.20 0.05 300 Principal Bangalore South

BioSpectrum Top BioSupplier Companies 2019 (Distributors)

Sr. Company Revenue Revenue % Category Location Region
No in 2018-19 in 2017-18 growth
(in crore) (in crore) Distributor New Delhi North
Distributor New Delhi North
1 DSS Imagetech Pvt. Ltd. 204.59 210.35 -3 Distributor New Delhi North
2 Premas Life Sciences Pvt. Ltd. 184.00 Distributor Mumbai West
3 Genetix Biotech Asia Pvt. Ltd. 101.00 145.00 30 Distributor Mumbai West
4 Saksham Technologies Pvt. Ltd. 61.96 Distributor Mumbai West
5 Esco Biotech Pvt. Ltd. 51.89 91.00 11 Distributor Mumbai West
6 Medispec India Ltd. 37.50 Distributor West
7 Lab Systems & Biotech (I) Pvt. Ltd. 22.40 53.26 16 Thane
8 Biolinx India Pvt. Ltd.
7.50 47.69 9

28.00 34

13.00 72

7.00 7

BIOSPECTRUM BIOSUPPLIERS
SURVEY AND METHODOLOGY

BioSpectrum India, a Filteration, Fermentation; their achievements in the past
leading B2B media Analytical Instrumentation -PCR financial years.
platform in Lifesciences machines, Chromatography,
space since 2003 Mass Spectrometer , Flow A detailed questionnaire
has re-launched its Cytometer, Spectrophotometer, (survey form) was sent to over
ranking special edition in June Centrifuges; Proteomics and 100 companies in this space to
2019 after a gap of 2 years. In this Genomics; Lab Furniture; capture the needed information
survey we looked at only the Bio Automation and Others areas for the analysis. This was
Suppliers market with companies catering to companies involved done during June 2019 (Sales
specializing in Lab consumables in biosciences/ life sciences revenues of all the companies
- Reagents & Chemicals, Kits, space. We have highlighted are in Rs Crore and Rs 70= 1USD).
Culture Media, Tubes, Pipette; the companies (both Principal Companies shared information
Bioprocess Technology – and Distributors) based on with us to the extent it was
possible by them.

# For all the ranking purposes the revenues considered for the analysis are biosciences/ life sciences sales and service figures. Where revenue figures were not available,
estimates were arrived in discussion with industry experts. Therefore, revenue wherever mentioned is not necessarily the total sales turnover of the company.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 25

WATERS INDIA PVT LTD 01

INNOVATING ANALYTICAL BIOSCIENCES
SCIENCE SOLUTIONS REVENUE

The Indian arm of US headquartered company Waters Corporation saw a ₹ 1200 crore
revenue generation of Rs 1200 crore in the last financial year 2018-19 in
the life sciences/biosciences space, as compared to Rs 1150 crore in the T ANIL KUMAR
previous year FY17-18, exhibiting a growth of approximately 5 per cent.
The total revenue of the company for 2018-19 was Rs 1300 crore. President, India Operations
Waters Corporation, established in the year 1958, is an organization with
over 60 years of history embracing innovation and quality service. The company
has been in the business of making innovative analytical instruments that
assist scientists in reaching their scientific goals, increase productivity, and earn
laboratory-based organizations a higher return on their investments in research,
development, and quality control.

The company offers services in the field of chemistry,
biopharmaceuticals, pharmaceuticals, health science diagnostics,
health science research, food, environment and forensic toxicology.
In the FY18-19, the company unveiled two new high resolution mass
spectrometry systems addressing the most challenging analytical
needs of leading R&D scientists. Apart from that, Waters has also
introduced a new cation exchange column line with specialized
consumables to simplify and improve the characterization and
monitoring of monoclonal antibody (mAb) therapeutics. The last
financial year also saw the introduction of the RenataDX Screening
System, a flow-injection tandem mass spectrometry (FIA-MS/MS)
system for rapid high-throughput analysis of extracted dried blood
spots and other human biological matrices.

In the new financial year, the company expects a growth of
10 per cent and plans to trickle down to the smaller pharma firms
and specialty chemical producers to offer its strong discovery,
clinical and generic medicine solutions. Waters believes that such
associations with these establishments, along with the packaging and
manufacturing units deliver benefit to all its stakeholders.

Waters foresees many opportunities in its sector with pharma
moving towards large molecule products and India becoming a hub
for global stability studies.

“In order to strengthen our technical expertise and also with the user
requirements in focus, we are looking forward to launch several new
products (instruments, columns and chemistries) catering across the
biological science segments. This includes biopharma and biotherapeutics
(BioTof Systems Ph2 Peptide Monitoring and then glycan intact, TQs micro,
Silverstone cyclic IMS, Xevo Qtof refresh with UNIFI and MassLynx), clinical
and biomedical research (Acoustic MS System, easy access IVD ready TQ
systems, high wire MS systems), pharma (prep and convergence SFC systems,

UHPLC IVD ready ones, TQs systems nano and micro), focused clinical
research [on the go sampling for tissues/food (QDa with LIVE ID)].”

26 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

02 THERMO FISHER
SCIENTIFIC INDIA PVT. LTD.
BIOSCIENCES
REVENUE COMMITTED TO
ANALYTICAL PRECISION
₹ 840 crore
During the FY18-19, US based Thermo Fisher Scientific Inc. generated a
AMIT CHOPRA revenue of Rs 840 crore in India for the life sciences/biosciences space
experiencing a double-digit growth in the last five years. The company’s
Managing Director Indian headquarter in Mumbai features more than two thousand
employees deployed in 40 plus cities and offices across 17 locations.
Thermo Fisher has established a considerable commercial footprint in India with
eight distribution centers, seven manufacturing facilities, five application labs and two
R&D centres. All this is supported by an extensive network of more than 400 channel
partners who ensure that products and services are easily accessible to the customers.
In India, the company has experienced double-digit growth in the last five years with
revenues greater than $300 million annually.
Thermo Fisher’s local manufacturing, R&D footprint is a testimony
to their commitment to building local capabilities in India. The
demonstration and manufacturing facilities in Mumbai, Bengaluru,
Gurgaon and Nasik serve the pre and post sales application needs of
the customers. Their expansion in the chemical business (acquired
from Qualigens) includes toll-conversion facilities and a new centralized
warehouse to provide easy access to stakeholders seeking to choose
the right products. In addition, the manufacturing facilities at Chakan
provide customized and integrated solutions for the environment
and process monitoring. The Thermo Fisher ‘Centre of Excellence’
for software and cloud technology development in Bengaluru and
the R&D centre for antibodies in Hyderabad are actively engaged in
developing cutting edge technology for their markets. They also have
a Chromatography Centre of Excellence in Ahmedabad to support
customers on method development and provide faster solutions to solve
complex R&D and quality challenges.
2019 has seen an increase in capabilities and capitalization of a
stronger environment to serve customers. In May 2019, Thermo Fisher
set up a new clinical trials facility in the Domestic Tariff Area (DTA),
Ahmedabad to better serve the pharmaceutical customer base in India.
This facility will help customers meet the increasing need for supply
chain management in the clinical trial space focused on local products
for India’s market. Through the company’s premier brands – Thermo
Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab
Services, the company offers an unmatched combination of innovative
technologies, purchasing convenience and comprehensive services.

“We seek to strengthen our presence in India to offer complete workflow
solutions for our customers. We are excited about the opportunities and
will continue to strive towards having the greatest impact on our business.
We want to exhibit our commitment to live our mission – To enable our
customers to make the world healthier, cleaner and safer.”

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 27

HIMEDIA LABORATORIES PVT LTD 03

DELIVERING BIOSCIENCES
EXCELLENCE AT DOORSTEP REVENUE

Mumbai based HiMedia Laboratories Pvt Ltd generated a revenue ₹ 650 crore
of Rs 650 crore during the FY18-19 in the life sciences/ biosciences,
exhibiting a growth of 32 per cent when compared to the revenue DR GANGADHAR
figure of Rs 490 crore generated in the previous financial year 2017-18. M. WARKE
Incorporated in 1973, HiMedia possesses world-class hi-tech
knowhow for manufacturing a complete range of chromogenic and HiVeg media CMD & Founder
products. The company has the broadest range of Vegetable Hydrolysate based
microbiology culture media (HiVeg), in the world, primarily due to its vertically
integrated manufacturing facility that produces a comprehensive range of Plant
and Animal based hydrolysates. Advanced products in the fields of Animal Cell
Culture, Plant Tissue Culture and Molecular Biology came next for HiMedia
as it grew. An excellent chemical testing facility equipped with the latest
analytical instruments enables HiMedia to deliver consistent ultra-pure
products.
The products at HiMedia are spread across a range of verticals
including microbiology, animal cell culture, plant tissue culture,
molecular biology, density gradient separation media, chemicals,
laboratory aids and equipment. The stem cell platform from HiMedia
is a One Point Solution (OPS) for Mesenchymal Stem Cell applications
in India, thus contributing to the growth of global Mesenchymal
Stem Cell industry. In addition, HiMedia with extensive research and
optimization has developed innovative column based extraction kits
to give very high yield and pure DNA.
In one of the many offices of HiMedia, there is a lab that is
working on basic research relating to plants – as an aid to promote
hydroponics. Hydroponics, or vertical farming, is not a new concept.
But the techniques that are being adopted in hydroponics are
improving every day. HiMedia has now opted to create another
company – Higronics – to focus on providing plant-specific nutrients.
With a presence in more than 140 countries, HiMedia is amongst
the top three brands in microbiology in the world. The end of FY18-19
saw HiMedia being conferred with the Pride of Maharashtra under
the category of “Best Company of The Year Award” for 2018 by the
Maharashtra Industrial and Economic Development Association
(MIEDA).

“HiMedia continues to work towards upgrading their portfolio as they are
of the reckoning of huge prospects within pharma and healthcare industry,

done by strengthened R&D and increased manufacturing capacities in all
segments, especially Ready Prepared Media coupled with enhanced products

in ATC, Molecular Biology and Microbiology Diagnostic Kits. HiMedia's
venture into Higronics aims to set one of the best examples towards unique

business cum CSR model.”

28 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

04 SARTORIUS STEDIM INDIA PVT. LTD.

BIOSCIENCES ACCELERATING
REVENUE PROGRESS IN LIFE SCIENCES

₹ 500 crore Sartorius generated a revenue of Rs 500 crore in India during the FY18-19
in the life sciences/ biosciences space exhibiting a growth of around 15
SIBASIS DAS per cent from the last fiscal. India along with China and South Korea
are the key sectors of business for Sartorius within the Asia-Pacific
Sales Director region. A revenue generation of Rs 3044 crore was recorded for the
(BioProcess Solution) APAC region during the 2018. India is the third largest market for Sartorius in the
Asia Pacific region.
India, SAARC
On the whole, Germany headquartered Sartorius Group has been annually
growing by double digits on average and has been regularly expanding its
portfolio by acquisitions of complementary technologies. For the FY18-19, the

company clocked in a global revenue of Rs 11000 crore in the life sciences/
biosciences sector.
Asia is a key focal area of Sartorius’ regional growth strategy. Asia has
a sizable growth potential, thus Sartorius has been heavily investing
here in sales infrastructure and plans to increase production capacity.
Bengaluru is home to one of the company’s centres of excellence
in bioprocess engineering and manufacturing. This facility caters to
serving customers’ requirements across the globe.
Sartorius AG plans to strategically grow its market share in Asian
& American markets, adding high-impact innovations to its portfolio
and extend manufacturing base in Asia. Its current focus includes
doubling of fluid management and filter capabilities at Yauco, Puerto
Rico plant; start of bag production at Beijing, China plant; extension
of bag production and logistics capacities at Aubagne, France;
new production & laboratory building for cell line development at
Ulm, Germany and extension of membrane production capacity at
Goettingen, Germany. This expansion will help Sartorius cater to the
growing demands of the biopharmaceutical industry both in India
and outside effectively in coming years.

“The range of our portfolio, along with our project planning, process
integration and validation services, helps us to partner with our
customers to provide them with total solutions and help them meet their
final goals of time to market, cost-effectiveness, quality assurance and
risk mitigation. Sartorius India has a highly qualified workforce that is
proficient in managerial and technical skills. This year, we will continue
leveraging these skills to support our customers in overcoming their
challenges and contribute positively towards accelerating the industry’s
growth and bringing better health to people while India moves towards a
better economic situation resulting in improved affordability of generic as
well as life style drugs.”

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 29

SHIMADZU ANALYTICAL 05
(INDIA) PVT LTD
BIOSCIENCES
CONTRIBUTING THROUGH REVENUE
SCIENCE AND TECHNOLOGY
₹ 468 crore
Shimadzu Analytical (India) Pvt. Ltd (SAIP), a subsidiary of Shimadzu Asia
Pacific Pvt Ltd, Singapore clocked in a revenue figure of Rs 468 crore YOSHIYUKI FUJINO
in the life sciences/ biosciences space showing a slight growth from
the revenue generated during FY17-18 at Rs 460 crore. Incorporated Managing Director
in 2006, SAIP caters to a large number of industries such as metals,
clinical research, electronics, food and beverages, automative, petrochemical,
pharmaceuticals and life sciences.

Shimadzu actively supports life science and biotech research in wide variety of
areas such as proteomics, genomics and metabolomics. In addition, the company
provides analytical instruments that meet the needs of the modern age by
helping to manufacture safe pharmaceuticals in compliance with IQ/OQ
requirements and other applicable regulations.

Following the virtues of Japan headquartered Shimadzu
Corporation, SAIP promotes unique and innovative solutions for
Biopharmaceuticals. The increasing interest in biopharmaceuticals
has resulted in significant growth in the cell culture market, as
scientists demand optimal media to ensure the viability of their
work. During the last financial year, the company released the new
C2MAP-2030 automatic pretreatment system for cell culture media
analysis. It automates the sample pretreatment process required prior
to simultaneous analysis of culture media components in a high-
performance liquid chromatograph mass spectrometer (LC–MS/MS).

In addition, FY18-19 also saw Shimadzu releasing the Nexera
Ultra High-Performance Liquid Chromatograph series, incorporating
artificial intelligence as Analytical Intelligence, allowing systems to
detect and resolve issues automatically. The Nexera series makes
lab management simple by integrating IoT and device networking,
enabling users to easily review instrument status, optimize resource
allocation, and achieve higher throughput.

This year, the company has added another element to its portfolio
in the form of MALDImini-1, the first commercially available compact
MALDI digital ion trap mass spectrometer. The MALDImini-1 fits in a
space the size of a piece of paper, while allowing fast high-sensitivity
measurements and detailed structural and qualitative analyses over a
wide mass range, even with sub-microliter sample volumes.

“We are targeting at 12 to 14 per cent growth for the company in the Life/
Bio sciences space. We intend to promote unique and innovative solutions for
Biopharmaceuticals and expand columns and consumables business. We see
great potential in these focus areas and hence an opportunity to provide.”

30 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

06 WEST PHARMACEUTICAL
PACKAGING INDIA PVT. LTD.,
BIOSCIENCES
REVENUE PROMOTING EFFICIENCY
AND RELIABILITY
₹ 370 crore
The India business for US based West Pharmaceutical Services Inc.
ALAGU SUBRAMANIAM generated a revenue figure of Rs 370 crore in the life sciences/
biosciences space during the FY18-19, showing a growth of 15 per cent
Managing Director when compared to Rs 322 crore generated in the previous fiscal. Formed
in 1923, West creates products that promote the efficiency, reliability
and safety of the world's pharmaceutical drug supply. West’s products play an
important part in the delivery of healthcare. The company manufactures 41
billion components annually and the top 50 biologics rely on West and Daikyo
components.

While the company has traditionally focused on marketing injectable
container solutions in India, it now sees the opportunity to further develop

its drug delivery business here. West launched several new products
during the FY18-19 to support the unique customer groups it serves.
The AccelTRA product line was extended to include additional vial
components. This product line helps Generics customers meet
increasing quality standards, ensure fast response to market volatility
and move product to market quickly.
In addition, the company also launched Westar Select, the latest
quality enhancement offering, which provides customers with a
tighter particulate specification, and is available through West’s
optimized global manufacturing network. Customers in India
have also expressed interest in Daikyo Crystal Zenith solutions, the
technologically-advanced cyclic olefin polymer containment and
delivery systems that offer an alternative to glass. West is also seeing
increased customer activity around its patient-controlled injection
platform, the SelfDose injector, as companies seek technologies that
make it easier for patients to self-inject. West’s Integrated Solutions
program is another highlight of the year. This program brings
together our primary packaging, device, analytical, regulatory and
contract manufacturing expertise in a single-source package that is
designed for any stage of the drug development lifecycle and across
all injectable formats.

“West is leading the injectable packaging and delivery trends in India
with laminated components like FluroTec Barrier Film Stoppers for vials
as well as prefilled syringes and will be launching shortly FluroTec
laminated injectable cartridge components. FluroTec closure technology
is the leading choice of barrier film for components used with biologic drug
products. For the Generics business we have developed AccelTRA rubber
formulation primarily focusing on Speed of Delivery, Quality and Simplicity.
With our global footprint including India manufacturing plant & warehouse,
West is well positioned to support growing Indian market with innovative
injectable packaging & delivery devices.”

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 31

DSS IMAGETECH PVT LTD 07

ADVANCING IMAGING BIOSCIENCES
REVENUE
New Delhi based DSS Imagetech generated a revenue figure of Rs
204.6 crore during the FY18-19 in the life sciences/ biosciences space ₹ 204.6 crore
exhibiting a decline in growth as compared to the revenue generation
of Rs 210.35 crore in the previous fiscal. This dip in performance is owed ARVINDER DHINGRA
to a number of challenges the company went through over the past
few years. Managing Director
One of the biggest principals of DSS, Olympus Medical has directly entered
the Indian market for Endoscopes and has started selling Endoscopy solutions
to customers themselves. However, due to DSS’s long standing relationship with
Olympus, the company has extended this relationship to represent Olympus
Medical in many cases in spite of a direct presence in India.
Also, one of DSS’s biggest contracts HIV-1 Viral Load Testing for NACO (Make
- Abbott Molecular), got converted to an upscaling project in January 2018.
Scaleup of Viral Load Testing Project by NACO (National AIDS Control
Organization), Ministry of Health & Family Welfare, Government
of India has been awarded to Abbott Molecular. Being Abbott
Molecular's channel partner in India, DSS is a part of this project with
respect to co-ordination, logistics and customer support. Although
the company’s regular annual sales has been absorbed into this
project and therefore is not reflecting in its sales anymore, however
this scaleup project is with a Rs 430 crore budget spread over 6 years.
From originally 7 NACO sites in the company’s regular business, DSS
now has a footprint into 64 NACO sites across India.
Conceptualized in 1938, DSS has offices in more than 13 cities
and a strong team comprising of 150 people. DSS’s product portfolio
encompasses a wide range of products for Life Sciences research,
Medical Diagnostics and Healthcare. The company is currently
maintaining focus on Research Imaging, Clinical Diagnostics, IVF and
Food Testing.
The products are spread across a wide range of applications
namely in the form of instruments, kits reagents, consumables,
accessories and software. DSS works closely with not only the leading
research and educational institutes of the country, it works with the
pharmaceutical and biotech industry as well.
DSS has been granted recognition by the Government of India
as a qualified R&D facility. This R&D unit has developed Molecular
Biology based test kits for food testing and human diagnostics as well
as Opto-electronics based tools for Medical and Diagnostics use.

32 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

08 PREMAS LIFE SCIENCES PVT LTD

BIOSCIENCES FOCUSING ON
REVENUE NOVEL TECHNOLOGIES

₹ 184 crore For the FY18-19, New Delhi based Premas Life Sciences recorded a
revenue figure of Rs 184 crore in the life sciences/ biosciences space,
PRAVEEN GUPTA growing at a rate of 27 per cent when compared to the revenue
generated during FY17-18 as Rs 145 crore.
Managing Director It was founded in 2005 by a group of professionals who had
diverse skills and a history of success across sectors like Energy, Biotech, and
FMCG markets. The organization has two major divisions – Contract Research
and Manufacturing (CRAMS) and Life Science Solutions. The Life Science
division was incepted for launching a bouquet of cutting-edge solutions for
the Indian Research and Applied markets. The firm's diverse product portfolio
encompassing an array of high end genomics equipment and associated
services has generated waves in the genetic diagnosis and research
markets.
In 2018, the company signed a distribution agreement
with a US based molecular diagnostics company, IncellDx. The
commercial partnership brings the power of cell by cell multiplex
diagnostics for solid tumours carcinomas that can now be analyzed
for molecular and protein biomarkers by flow cytometry. The
distribution agreement includes IncellDx's patented single-cell
assays for quantifying PD-L1 on tumour cells and immune cell
subtypes; patented single-cell assay for HPV E6/E7 mRNA detection
in cervical samples; and, and its incellPREP single-cell preparation
kit for solid tissues including tumours.
Premas has been the national distributor for Illumina for a
while now. The American company develops, manufactures and
markets integrated systems for the analysis of genetic variation and
biological function. Premas has been able to successfully install an
increased number of genome sequencing platforms in many key
national institutes in India. The company is of the view that India is
very well poised to take leadership in Genome informatics based
economy by taking advantage of the demographic dividend.
The company is also running a partnership with Hamilton
Robotics, a pioneer in liquid handling equipment and laboratory
automation technology. Premas has been distributing Hamilton
products not only in India but Nepal, Bangladesh and Sri Lanka as
well.

“We strongly feel that our focus on Genomics has a huge potential in the
Indian market. We anticipate to continue our CAGR of 25-30 per cent for
next 3-4 years and key drivers of our growth are Large scale whole
genome sequencing efforts by the Government, Biodiversity projects,
Indian Microbiome project and Clinical adoption of Genomics (in Oncology,
Reproductive health, HLA typing , Infectious disease and rare disorders)”.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 33

EPPENDORF INDIA PRIVATE LIMITED 09

PROACTIVELY SUSTAINABLE BIOSCIENCES
REVENUE
Eppendorf India generated a revenue of Rs 145 crore during the FY18-19 in
the life sciences/ biosciences space marking a growth of approximately ₹ 145 crore
11 per cent when compared to Rs 131 crore generated in the FY17-18. The
Indian arm of Germany headquartered Eppendorf AG was established in V SANKARANARAYANAN
2003 to cater and be closer to the customers of the sub-continent and
continue being an expert partner in life sciences laboratories. Head of Sales
With a workforce of 165 employees, Eppendorf India is strongly committed
towards skill development. As a result, FY18-19 saw the company entering into
agreements with two institutes in Chennai- Rajalakshmi Engineering College
and Sree Sastha Institute of Engineering and Technology, for training students of
Biotechnology on various modules. As part of this arrangement, a team of experts
at Eppendorf is offering training programmes for students on modules such as
Good Liquid Handling Practices, Art of Spinning (Centrifugation), Quantify in a
new light (Detection of Biomolecules), Advanced PCR and Cell Culture.
Head quartered in Chennai, the company has offices in all major
cities. Pipette calibration centres are located at Chennai, Bengaluru,
Hyderabad, Pune and New Delhi. In addition, a mobile pipette
calibration facility is available in Chennai and Bengaluru, which is
an innovative, first of its kind, service taken to door steps of smaller
labs to provide onsite calibration and certification. Laboratory and
training centre in Chennai provides the flexibility to train customers
on specific high-tech topics such as micromanipulation and liquid
handling automation. Moreover, the lab also serves for demonstration
purposes as a continuing exhibition of state-of-the-art research
tools. Eppendorf India participates in many marketing events like
exhibitions, conducting workshops, seminars and presentation for
customers.
Beyond the sub-continent, Eppendorf India is also associated
with markets of Bangladesh, Sri Lanka, Nepal, Maldives, Bhutan
and Sub-Saharan Africa working very closely with various dealers in
these countries, providing pre-sales and post-sales support. With the
acquisition of New Brunswick Scientific by Eppendorf in late 2007,
Eppendorf India has been a one-point pit stop for customers for both
Eppendorf and New Brunswick products since 2008.

“For the first half of the year, numerous product launches are planned
that will contribute to the further positive development of our sales.
Digitalization and Networking are future-oriented topics that are growing

more and more important to the success of our products as their use
in everyday lab work is increasing. We therefore work towards these
topics intensively. Eppendorf continues to invest strongly in line with our
strategies for life science space and our goal is to achieve growth above
the industry average. At present, currency fluctuations, influx of low cost
equipment, meeting customers’ service needs are the common challenges /

opportunities in this sector”.

34 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

10 GENETIX BIOTECH ASIA PVT LTD

BIOSCIENCES MAINTAINING GROWTH
REVENUE
New Delhi based Genetix Biotech Asia Pvt Ltd recorded a revenue
₹ 101 crore figure of Rs 101 crore in FY18-19 in the life sciences/ biosciences space
exhibiting a growth of 11 per cent from the last fiscal’s revenue at Rs
ARUN PRAKASH 91 crore. During FY18-19, the company clocked in revenue sales of Rs
63 crore for lab consumables such as reagents and chemicals (Rs 45
CEO crore), kits (Rs 5 crore), culture media (Rs 50 lakh), tubes (Rs 2 crore), pipettes and
tips (Rs 50 lakh) and others (Rs 10 crore); around Rs 20 crore for bioprocessing
technology including filteration (Rs 20 crore) and fermentation (Rs 40 lakh); and
approximately Rs 18 crore for lab instrumentation comprising of PCR machines (Rs
10 crore), centrifuges (Rs 1 crore) and others (Rs 7 crore).
The last financial year also saw the company launching several new products
for distribution and few products especially for animal and diagnostic category.
With a team of 115 employees, the company has its workforce distributed in a
number of areas such as R&D (2), manufacturing (12), sales (60), support (16)
and operations (25).
Genetix offers products in a wide range of categories such as
molecular biology kits and reagents, biochemical, lab chemicals,
media & sera, plastic wares, glass wares, chromatographic columns
and accessories, fermenters, filtration products, antibodies and ELISA
kits, diagnostic kits, lab equipment, gloves and lab utilities, to name
a few.
The products offered by Genetix are used across multiple
applications namely DNA & RNA purification, PCR, cloning, western
blotting, plant tissue culture, cell culture, chromatography, filtration,
diagnostics and liquid handling.
Genetix has its own warehousing and logistic facility in New
Delhi which ensures the company to supply any product to farthest
corner of India in shortest possible time and mostly by one day.
The company stocks and sells more than 16,000 SKUs comprising
of perishable and non-perishable products as well as instruments.
The company takes credit for creating well trained human resource
for the industry in the last 25 years and for creating completely new
business model in the Biotech Industry. Genetix has implemented
ISO Quality Systems, GMP (Good Manufacturing Practices) and SAP
for better CRM & Operations..

“We have high growth plans for Industry segment with multiproduct new
business strategy, along with high growth expectations in diagnostic
segment with new initiatives and creating diagnostic as separate vertical.
We expect a growth of 25 per cent in this new year with government
funding and buyers’ market because of innumerable small mushroom
suppliers being some of the challenges and opportunities in our sector.”

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 35

11 SAKSHAM TECHNOLOGIES PVT LTD

REVENUE Mumbai based Saksham Technologies clocked in a revenue figure of Rs 62
crore during the FY18-19 in the life sciences/ biosciences space, growing
₹ 62 crore at a rate of 17 per cent when compared to the revenue generated in the
previous fiscal at Rs 53 crore.
SAMEER MAHESHWARI Founded in 1992 with an objective to provide quality instruments with special
emphasis on after sales service support, today Saksham Technologies has become
Chief – Customer Support a well-recognized name in the trading of superior quality laboratory equipment.
Widely used in hospitals, research labs, clinics and health care units, the
equipment are appreciated for accurate output, high performance and efficiency,
safe and easy application, durability and low maintenance.
Saksham has signed agreements with Airinspace in France for their air
decontamination Units; with Cesco Bioengineering in Taiwan for their Bioreactors;
with GT Scien in Korea for their Clean Air Systems; with DaiHan Scientific in Korea
for their laboratory tools; with Labor Security System in Italy for their Solvent
Storage Cabinets; with PlasLabs in USA for their Glove Boxes and Isolators; with
Kambic in Slovenia for their growth chambers; with Pre-Sens in Germany
for their Sensor Probes, Transmitters and Complete Systems; with Lamy
Rheology in France for their rheometers and viscometers; and with
Steelco, Italy for their washers and disinfectors.

12 ESCO BIOTECH PVT LTD

REVENUE During the FY18-19, Mumbai based Esco Biotech generated a revenue of Rs
52 crore in the life sciences/ biosciences space showing a growth of 15 per
₹ 52 crore cent with respect to the revenue generated during the FY17-18 at Rs 47.6
crore.
Esco Group is a renowned Singapore-based life science company with
a diversified portfolio and sales in over 100 countries. As a world leading
manufacturer of laboratory and biopharma equipment, and IVF medical devices,
Esco offers tailored solutions that fit the needs of laboratories. With the most
extensive product line in the industry, its products have passed a number of
international standards and certifications. Esco operates under ISO 9001, ISO
14001 and ISO 13485.
In 2018, Esco launched a number of new products such as Bio Booth, a Class II
Walk-In Containment Enclosure; Sputum Booth; BioPass Pass Through; upgraded
Turbulent Flow Aseptic Isolator (TFAI) with Pod Flange- a flexible and detachable
worktop; Cell Processing Isolator; Ascent Storage Cabinet; Miri Time Lapse Mini
Benchtop Incubator with 6 Chambers or 12 Chambers; and Miri Time Lapse Mini
Benchtop Incubator with SAFEsens for pH monitoring.

SAMEER MAHESHWARI

Chief – Customer Support

36 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

13 MEDISPEC (I) LTD

REVENUE For Mumbai based Medispec India, the revenue generation during the
FY18-19 was recorded at Rs 37.5 crore in the life sciences/ biosciences
₹ 37.5 crore space. In comparison to Rs 28 crore generated in the previous fiscal,
the company showed a growth rate of 35 per cent.
VIPUL CHATBAR Incorporated in 1995, MEDISPEC deals with marketing and services of
products for the life sciences industry such as Microplate Instrumentation,
Chief Executive Officer (CEO) Gel Documentations Systems, Freezers, Incubators, Biosafety Cabinets,
Imaging, Thermal Cyclers, Liquid Handling, Liquid Base Cytology system
& other Diagnostic products that help accelerate the pace of scientific
discovery and meeting the challenges ranging from complex research to
routine testing and field applications. Having pan-india operations, the
company works exclusively with brands like BioTek, Nuaire, Syngene, BTX.
After launching new Gel Documentation systems and Cell Imaging
Multi Mode Readers in 2018, the company plans to increase its product
portfolio in the Genomics and Molecular Diagnostics Market. Medispec
also intends to expand its business in the SAARC countries.
With a team of 30 people, a major challenge currently being
faced by Medispec is in the form of the limited government
funding being imparted to the key research institutes in India
which in turn affects the company’s sales.

14 ANALYTICAL TECHNOLOGIES LTD

REVENUE Gujarat based Analytical Technologies Ltd recorded a revenue
generation of Rs 28 crore during the FY18-19 in the life sciences/
₹ 28 crore biosciences space, exhibiting a growth of approximately 33 per
cent in comparison to Rs 21 crore generated in the previous fiscal.
SIVA PRASAD PATNAM
Initiated in 2007, the company generated bulk of its revenue during
Chief Executive Officer (CEO) the FY18-19 from the sale of products in the filteration, chromatography
and spectrophotometry space. The company also launched a new
analytical product this year-LCMS XRD LPSA.

With a workforce of 120 employees, Analytical Technologies is aiming
at carrying out annual sales worth Rs 300 crore in the next three years.
In the midst of these plans, the company also faces the challenge of
competing with foreign multinationals like thermo fisher shimadzu etc.

Analytical Technologies is involved in the supply and export of
Analytical, Chromatography, Spectroscopy, Biotechnology, Biomedical,
Clinical Diagnostics and Material Science & General Laboratory

Instrumentation. Main products of the company include Lab setups on
turnkey basis, chromatography, Spectrophotometers, Amino Acid
Analysers, Particle Size Analysers, Particle Counters, Polarimeter,
micro plate elisa readers etc.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 37

15 LAB SYSTEMS & BIOTECH (I) PVT LTD

REVENUE For the FY18-19, Mumbai based Lab Systems & Biotech India recorded a
revenue figure of Rs 22.4 crore in the life sciences/ biosciences space,
₹ 22.4 crore growing at a high rate of 70 per cent when compared to the revenue
generated during FY17-18 at Rs 13 crore.
JAY B VAKIL Started in 1996, the company offers a wide range of quality products
such as spectroscopy, chromatography, water testing, elemental analysers,
Managing Director phase monitor, super critical fluid and high pressure reactor.
Lab Systems & Biotech India provides quality analytical solutions to
a number of industries along with excellent after sales and application
support. Through innovation and introduction of new technologies the
company has been on a path of continuous and fast growth. Its success
and reputation is built on a commitment to customer satisfaction through
high quality of products. The company has successfully executed and has
been supporting bulk package orders for a range of Lab Analytical solutions
in India and overseas.
Over the years, the company has received orders from a number
of pharma players namely Alkem, Cipla, Ajanta Pharma,
Wockhardt, Mylan etc.

16 ZEBA LAB FURNITURE PVT LTD

REVENUE Kochi based Zeba Lab Furniture clocked in a revenue figure of Rs 13 crore
during the FY18-19 in the life sciences/ biosciences space exhibiting a
₹ 13 crore growth of 30 per cent when compared to Rs 10 crore generated in the
previous year.
JIJI MANIKKATH Zebalabs has a wide range of products that includes lab bench, lab chair,
chemical storage cabinets, fume hoods, lab fittings, anti-vibration tables,
Managing Director ductless fume hoods, lab stool, fume cupboards, eye wash units, lab showers,
lab sinks and various lab furniture and lab equipment.
The company commands an excellent brand image across Middle East,
Far East Africa and Indian subcontinents, by winning the trust of more than
700 customers over 27 nations with its high quality products and dedicated
services.
The company caters to a number of sectors such as Agricultural,
Archeology, Aviation and space science, Biotechnology, Pharma & Cosmetics,
Cement and concrete, Container & mobile laboratories, Educational
Institutions, Fisheries, Food & Beverages, Forensic Science, Hospital &
Healthcare, Microbiology, Paint and Coatings, Petroleum & Oil, Poly-
film Industries, Research labs, Robotics, Testing Services, Textiles
and garments, Treatment plants and Veterinary.

38 COVER STORY BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

17 APS LIFETECH

REVENUE Pune based APS Lifetech clocked in a revenue figure of Rs 7.8 crore
during the FY18-19 in the life sciences/ biosciences space, growing at
₹ 7.8 crore a rate of 25 per cent when compared to the revenue generated in the
previous fiscal at Rs 6.2 crore.
DR PARITOSH SHEKHAR Out of the revenue generated during the FY18-19, the bulk came in
with the sales of kits, reagents and chemicals followed by the sales in
Director fermentation, PCR machines, centrifuges, genomics and automation
space. As part of its upcoming plans, the company intends to open an
office in the US this year.
Incorporated in 2012, the company currently has a team strength of 18
distributed in a number of areas namely R&D (3), manufacturing (7), sales
(4), support (2) and operations (2).
APS Lifetech is focused on Drug discovery, Bio Consulting and Bio
Services along with product distribution in PAN India for Medical devices,
laboratory instruments, antibodies, reagents and diagnostic products
under one umbrella solution. Services in Microarray, NGS, Flow
cytometry, RT PCR, Genomic and Primers solution, food safety,
peptide synthesis are some of the major activities offered by
APS Lifetech.

18 BIOLINX INDIA PVT LTD

REVENUE For the FY18-19, Mumbai based Biolinx India recorded a revenue figure of
Rs 7.5 crore in the life sciences/ biosciences space, growing at a rate of 7
₹ 7.5 crore per cent when compared to the revenue generated during FY17-18 at Rs
7 crore.
GIRISH NAIR Incorporated in 2008, Biolinx serves as a distributor for Cell Culture
support instruments. The company offers a wide range of products such
Director as fermenters, automated glassware washers, flame photometers, multi
angle light detection systems (MALS), field flow fractionation Systems (FFF),
chlorine di-oxide fumigation systems, liquid-solid biowaste systems, vacuum
homogenizer, viscometer, rheometer, refractmeters, density meters, and
titrators, to name a few.
With a team size of 15, spread across sales, support and operations, Biolinx
recently launched a new product- cytotoxic cabinet. The company is gearing
up to explore newer markets this year with new products in its pipeline.
Over the years, Biolinx has received major orders from Reliance Industries,
Zydus Cadila, Lupin, National Institute of Pharmaceutical Education and
Research (NIPER), BV Patel Pharmaceutical Education and Research
(PERD), Bhabha Atomic Research Centre (BARC), Kokilaben
Dhirubhai Ambani Hospital & Medical Research Institute (KDAH),
and National Centre for Cell Science (NCCS).

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com COVER STORY 39

19 BHAT BIO-TECH INDIA PVT LTD

REVENUE Bengaluru based Bhat Bio-Tech generated a revenue figure of Rs 59
lakh during the FY18-19 in the life sciences/ biosciences space. The
₹ 59 lakh company has recently forayed into this area with the launch of Life
Science Reagents and Kits, Molecular Diagnostic Kits and Reagents, Low Cost
DR SHAMA BHAT Glucometer and Strips.
The company commenced its operations in 1994 and is now specialized in
Director the design development, manufacture and marketing of diagnostic products
and biotechnology based products. The product portfolio comprises of
diagnostic test devices for various types of tests like Pregnancy, HIV, Hepatitis,
Malaria, Dengue, Chikungunya, Swine Flu (H1N1), Syphilis, TB, Cardiac Markers,
Dry Chemistry, Bio-Chemistry, Haematology & Immunology and ELISA`S used
in the analysis of body fluids in human. In Life Science related products, the
company manufactures and markets Genomics (DNA, RNA), Proteomics and
Lab Instruments.
The company has an employee strength of 264 distributed across several
areas such as R&D (38), Manufacturing (172), Sales (32), support (8) and
operations (14). The company expects to grow at a rate of 20-25 per
cent within the life sciences space in the coming years.

20 ANGA BIM & LAB ENGINEERING
DESIGNS (OPC) PVT LTD
REVENUE
For Bengaluru based Anga Bim & Lab Engineering Designs, the revenue
₹ 20 lakh generation during the FY18-19 in the life sciences/ biosciences space
was Rs 20 lakh, marking a huge growth for the company when
compared to the revenue generation of Rs 5 lakh in the previous fiscal.
The total revenue of the company during the FY18-19 stands at Rs 35
lakh. Initiated in 2017, the company primarily deals with furniture items such
as Fume Hood, Laboratory Furniture and Clean Rooms.
The company has workforce of 8 employees spread across sectors such
as R&D (1), manufacturing (4), sales (1), support (1) and operations (1). With
new launches in its basket, the company anticipates a further growth rate of
10 per cent in the life sciences space this year.

YAMINI K

Managing Director

Smart Technologies for
Sustainable Development

11th

22 - 25 November 2019

Reshimbagh Ground, Nagpur

Central India's Largest Agri Summit

Grand National Agri Expo C
•Participation of over 400 organisations from Multinational M
Y
Companies, Corporates, Research Institutes. Agri Universities, CM
NGO, Various Departments of Central & State Govt. etc MY
CY
•Visited by Lakhs of farmers from all over India CMY
K
Free Workshops for Farmers
•Workshops on important topics to be conducted by

Agri Experts to educate, encourage & empower farmers

•Extended workshops on certain current topics of

impor tance

•Success stories of farmers

•One Day Conference •Expert panel discussion

Animal Husbandry Pavilion YoBuTorooSdktaayll
Special Pavilion For MSMEs Registered Units
MSME Approved Event
One Day Conference on Micro, Small &
Medium Enterprises and Dairy Development

www.agrovisionindia.in

Agrovision Secretariat : Nagpur : 97647 96709 Ph: 0712-2544 929 I Pune : 99232 02884 Ph: 020-2729 1769 I Delhi : 95997 79029 Ph : 011-4354 2737
Email : [email protected] / [email protected] Follow /@agrovisionindia

Organised By Supported By

Ministry of Agriculture & Ministry of Micro, Small &
Farmers Welfare, Govt. of India Medium Enterprises, Govt. of India

NEW! Saunders® P345 is a modular polymer pneumatic actuator developed to provide superior
performance in Bioprocess applications and deliver major TCO bene ts in terms of plant
COMPACT ACTUATOR e ciency and air consumption. 4.5 bar operating air requirement delivers savings in air consumption
and maximises plant e ciency. Size Range DN8 0.25” to DN100 4”. Closure performance aligned with
needs of Bioprocessing industry. Elastomer Diaphragms 10 bar 100% ΔP, PTFE Diaphragms 8 bar 100% ΔP.

www.saundersvalves.com

P345 Compact Polymer Actuator

Key Features and Bene ts

• Fully consistent operation at low operating • Signi cant reduction in pneumatic (air) set
pressure 4.5 bar up cost and infrastructure

• Highly compact dimensional envelope to • 10% annual energy savings through
minimise internal wetted area and hold up reduced air consumption
between associated valves
• Zero maintenance to maximise security
• Stainless Steel body/bonnet interface suitable and reliability of operation
for 2 Way and machined block con gurations
optimises security and reliability

Crane ChemPharma & Energy, Saunders® | Crane Process Flow Technologies India Ltd. | www.saundersvalves.com
Solitaire 6th Floor, S.No. 131/1+2, ITI Road, Aundh, Pune – 411007 | Switchboard: +91 20 7120 7120

42 ACADEMIC NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

AHPI, PHFI, IIT-D collaborates with
IISc, IIST university in Taiwan
introduce
health-tech Indian Institute of Technology - an academic and student exchange
course Delhi (IIT-D) and National Chiao will be developed through the JDP
Tung University (NCTU), Taiwan whereby students who successfully
Association of have signed a Memorandum of completes all the requirements of
Healthcare Providers Understanding (MoU) to establish the programme will be awarded a
of India (AHPI) along and offer a Joint Doctoral Degree joint degree for the thesis by both
with Public Health Programme (JDP). The MoU has institutions. Both institutions also
Foundation of India been jointly signed by Prof. V. seek to work together and carry out
(PHFI), Indian Institute Ramgopal Rao, Director, IIT-Delhi joint research & academic activities
of Science (IISc) in and Prof. Mau-Chung Frank Chang, in a mutually beneficial way and to
Bengaluru and Indian President, National Chiao Tung look for synergies across the doctoral
Institute of Space University, Taiwan. Under the MoU, programmes of each other.
Science and Technology
(IIST) in Trivandrum ICMR-NIE to strengthen
are developing a research capacity in India
certificate programme
in healthcare National Institute of Epidemiology (NIE), a premier institute of Indian Council
technology. of Medical Research (ICMR) has announced the launch of Massive Open
The Memorandum of Online Course (MOOC) ‘NIE-ICMR eCertificate’ courses– called as NIeCer
Understanding (MoU) courses with the aim to strengthen the research capacity in India. The first
was signed in the in the NIeCer series, Health Research Fundamentals (NIeCer 101) –is a basic
presence of Prof. Kurien
Issac, Senior Professor level course in health research methods. The
& Dean, Aerospace course is designed and conducted by faculty
Engineering, IIST; members from ICMR School of Public
Prof. Anurag Kumar, Health at ICMR-NIE. It will explain the
Director, IISc; Sandeep fundamental concepts in epidemiology and
Bhalla, Director, bio-statistics related to research methods.
Training, PHFI; Dr V This course will provide an overview of steps
C Shanmuganandan, and principles for designing bio-medical
Advisor, AHPI, among and health research studies among human
others. participants. The course will be useful to
The course will be any current or potential health researchers including students, clinical/ public
tailored for both health/ laboratory researchers, physicians, research associates, allied health
clinical and managerial professionals, scientists, statisticians, ethics committee members and project
healthcare professionals managers. The course is open to undergraduate students in Medical/Dental/
with the primary AYUSH disciplines or graduates in any other discipline as well.
objective to enhance
their knowledge, skill
and core competencies
in healthcare
technology. Module
development by the
technical and academic
partners will be taken
up in the subsequent
months.



44 SCIENCE NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

INST creates hydrogel to IIT-Mandi
improve stem cell uptake designs
nano-capsules
Scientists from the Mohali-based Institute of Nano Science against cancer
and Technology (INST) have devised a method to encapsulate
adult stem cells called Mesenchymal Stem Cells (MSC) in an A research team from Indian
injectable hydrogel. In preliminary studies, it has been found Institute of Technology (IIT)
that the hydrogel exhibits cell viability and can support long- Mandi has developed complex
term survival of stem cells. The injectable hydrogel has been nano-dimensional capsules that
derived from natural materials like cellulose and chitosan can be used for multimodal
(found in seashells) and it biodegrades in about a month. The imaging and treatment of tumours.
hydrogel was fabricated by connecting an aldehyde group with Their work paves the way for better
an amino group by employing a method called the Schiff base understanding and development
reaction. The hydrogel addresses the issue of the long- term of theranostic techniques for
survival of adult stem cells in simulated cultures that mimic cancer and other diseases.
the actual body tissue. The scientists observed that cells survive Theranostics is an emerging
and multiply for a period of one month, which is sufficient time field in medicine, especially
for tissue regrowth. in oncology, and combines
'diagnostics', the detection of
abnormalities and maladies,
with 'therapeutics', treatment
of the malady. The researchers
have developed a 'smart' nano-
material that can serve as an
effective theranostic agent. Their
plasmonic nano-capsules have
functionalities that make them
useful in diagnosis through a
technique called Surface-Enhanced
Raman Spectroscopy, or SERS,
in addition to carrying a cancer
drug in it, which can be released
simultaneously.

IIT-G develops new detection kit for malaria

A group of researchers from Indian to specifically capture the antigen syringe, the blue dye turns pink.
Institute of Technology (IIT) released by the parasites in the The dye is then adsorbed over a
-Guwahati has developed a simple blood of malaria patients. When modified chromatographic paper.
detection method for malaria that the captured antigens interact The formation of pink colour on the
uses an instrument when in the with specific substrates inside the paper is a direct indication of the
lab or a piece of chromatographic presence of parasites in the blood
paper when in the field. The kit serum. The intensity of the colour
can be used to detect Plasmodium increases when the concentration
parasite, which causes malaria and of antigen is high. This kit also has
also specifically detect Plasmodium high stability in hot and humid
falciparum. Using an ordinary conditions. When mass produced,
syringe fitted with a small magnet, the kit can be cheaper than the
magnetic beads and few chemicals existing rapid detection test kit
inside, the researchers were able available in the market.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com SCIENCE NEWS 45

JNU, DRDL collaborate BARC experts
to create more potent develop nanosilver
Anthrax vaccine coating to kill bacteria

A group of scientists from the Defence Research Researchers at the Mumbai based Bhabha Atomic
and Development Laboratory (DRDL), Mysuru and Research Centre (BARC) have developed a new
Jawaharlal Nehru University (JNU) has developed method to prepare silver nanoparticle loaded
a new vaccine against anthrax. It is claimed to be antibacterial powder that can be applied on surfaces.
superior over existing vaccines as it can generate They deployed the spray-drying
immune response to anthrax toxin as well as its technique to synthesize silver
spores rather than the toxin alone. The scientists nanoparticles attached ceramic
stitched together portions of two genes: protective microparticles. In this process,
antigen protein and protein present in outer layer gum arabic - an eco-friendly
of spore. The protein thus produced was fusion of biopolymer obtained from the
the two proteins and was injected into mice. Acacia tree – was used. Gum arabic
helps in chemical reduction and
attachment of silver nanoparticles
to the silica substrate. The
antibacterial powder could
potentially be used to clean water
and in waste management. It could be mixed in
paints and applied to surfaces where chances of
infection are high, such as walls in hospitals, kitchens
and toilets to give them antimicrobial coating.

46 PEOPLE NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

NEW MINISTERS AT NAMO 2.0 Ashwini Kumar
Choubey takes
Dr Harsh Vardhan takes charge as MoS
over Health Ministry for Health and
Family Welfare
Dr Harsh Vardhan has been appointed as the Minister of Health
and Family Welfare, Minister of Science and Technology and Ashwini Kumar Choubey took
Minister of Earth Sciences. Jagat Prakash Nadda had held charge as the Minister of State
the portfolio in the health cabinet before. Food Safety and for Health and Family Welfare
Standards Authority of India (FSSAI) is an autonomous body at Nirman Bhawan, on June 4.
established under the Ministry of Health & Family Welfare. A Choubey stated that he will carry
major pioneering initiative of Dr Harsh Vardhan was his act on with his efforts to implement
of implementing WHO’s Essential Drug Programme, which the mandates of Ayushman Bharat
revolutionised governments’ attitudes on public health care. Under and will now further push for the
the concept, maximum budgetary outlay was apportioned to those benefits of Ayushman Bharat to
drugs most needed by the people. His life-long commitment to reach the very last mile people;
polio eradication continues notwithstanding his being in power or those people who still are unable
not. To this end, he also served the South-East Asia to access the services provisioned
office of World Health Organisation (WHO) as for them through this revolutionary
an Advisor. He is the first Indian to have been programme of the Govt.
nominated to the prestigious WHO body, the
Strategic Advisory Group of Experts (SAGE), in
which capacity he counseled the international
body on developing policies on vaccines and
biologicals. Apart from this, he has served on
the Global Technical Consultative Group and
the Technical Consultative Group of the South
East Asia region for polio eradication. This is
the highest body of WHO dedicated to the
elimination of polio.

Sadananda Gowda heads Ministry Mansukh L. Mandaviya
for Chemicals and Fertilizers in-charge as MoS for
Chemicals & Fertilizers
DV Sadananda Gowda is the cabinet
minister for chemicals and fertilizers Mansukh
in Prime Minister Narendra Modi’s Mandaviya
new government. The Ministry of continues to take
Chemicals and Fertilizers in India charge as the
is the administrative unit of three Minister of State
departments namely- Department for Chemical
of Chemicals and Petrochemicals, & Fertilizers in
Department of Fertilisers and Government
Department of Pharmaceuticals. In of India. He is
2014, he joined the Narendra Modi well known for
government as a cabinet minister, his intellectual
handling Railways, Law & Justice, analysis
Planning and Statistics & and thought
Programme Implementation. After leadership, which
Ananthkumar’s death, he was he also exhibited in his speech on “2030
given the additional responsibility Agenda for Sustainable Development” at
of Chemicals & Fertilisers. the United Nations.

BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com PEOPLE NEWS 47

ICMR Head wins Dr Vatsal Shah to
public health award lead Siro Clinpharm’s
US operations
Director General of the Indian Council of Medical
Siro Clinpharm has named Dr Vatsal Shah as
Research (ICMR) Professor Balram Bhargava has the head of its US operations. Siro, one of India’s
leading contract clinical research organisations
been awarded the 2019 Dr Lee Jong-wook Memorial (CROs), has its US headquarters in New Jersey,
where Dr Shah will be based, and has been focusing
Prize for Public Health at the 72nd World Health on that market as
part of its aggressive
Assembly in Geneva in June 2019. He bagged the expansion. Dr Shah is
currently the COO of
award for his achievements as a Siro Clinpharm and
will transition to the
clinician, innovator, researcher Global Chief Operating
Officer’s role to lead
and trainer. Prof. Bhargava is also this expansion. Dr
Shah is a physician
a senior consultant cardiologist at and has more than
20 years of varied experience encompassing all
the All India Institute of Medical phases of clinical research and all document types
for medical writing – from academia as well as
Science (AIIMS). He is reported as all industry perspectives (pharma, CRO, business
process outsourcing).
a leader in the field of biomedical

innovations in India. He was the

force in the establishment

of the Stem Cell Facility

at AIIMS which was,

reportedly, the first

centre in the world

which initiated

treatment for dilated

cardiomyopathy

patients.

48 SUPPLIERS NEWS BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

BD opens Thermo Fisher to advance
disease biomarker validation
CoE in Flow
Thermo Fisher Scientific, the consistent performance during
Cytometry at extended studies, microflow
world leader in serving science, LC-MS provides a balance of
IISER Pune speed, sensitivity and throughput
and Newomics, a leading for biomarker discovery and
BD Life Sciences-Biosciences, a validation in translational
segment of BD (Becton, Dickinson supplier of microfluidic emitters proteomics laboratories. The
and Company), in collaboration collaboration brings together
with Indian Institute of Science for liquid chromatography- Thermo Scientific microflow LC-
Education and Research (IISER) MS systems and Thermo Scientific
has launched the IISER- BD mass spectrometry (LC-MS) Nanospray Flex ion source with
Centre of Excellence (CoE) Newomics' multi-nozzle emitters
in Flow Cytometry, a critical applications, will combine to achieve the benefit of nanospray
component of research. The state- flowrates, with the improved
of-the-art CoE was launched in their expertise and innovative throughput and robustness of
Pune that will provide training to microflow LC-MS.
researchers and young scientists technologies to develop and
to enhance their expertise in flow
cytometry and focus on frontier optimize sensitive, robust and
areas in Biological Sciences.
The CoE is well equipped with reproducible microflow LC-MS
a comprehensive range of
flow cytometer instruments workflows for the validation
like BD FACSAria Fusion, BD
FACSCelesta and BD Accuri of disease biomarkers. Unlike
C6 Plus that will address both
current and future needs for nanoflow chromatography,
research applications. IISER Pune
is another purposeful addition to which slows the speed of analysis
BD’s existing CoEs at NCCS-Pune,
Calcutta University - Kolkata, and can be difficult to maintain
AIMS-Kochi, PD Hinduja-
Mumbai and NCBS-Bengaluru.

SCHOTT increases pharma tubing production in India

The German technology strategy of its pharma tubing and the tank will feature the unique
group SCHOTT is investing packaging business segments. In big data approach, perfeXion.
an additional double-digit line with the company’s aim to The process, which has been
million-euro figure into a manufacture zero defect tubing, rolled-out globally by SCHOTT
new glass tank at its tubing since 2017, ensures 100 per cent
manufacturing plant in Jambusar, quality control of each tube on the
Gujarat. The expansion follows line by using cameras, laser and
recent investments at the site IR inspection systems. The new
including the construction of tank will be built and equipped
another additional tank facility with the latest state-of-the art
just last year. Production of machinery, according to the high
pharmaceutical FIOLAX tubing standard of all SCHOTT Tubing
from the new tank is scheduled to production sites. Besides the tank
begin in the second half of 2020. facility, the investment includes
The capacity expansion is part an extension of the batch house,
of the company’s global growth warehouses and a new chimney.

Inviting Maharashtra
Entrepreneurship ICONS

Maharashtra Economic Development Council (MEDC)
Mahaudyam Award is the first and only truly regional award of its kind,
MEDC Mahaudyam Award celebrates those who are building and
leading successful, growing and dynamic businesses, the exceptional
individuals who turn ideas into action, creating a flow-on of success for
those around them - generating employment and industry growth,
driving the economy and progressing society.

MEDC Mahaudyam Award will provide an exclusive opportunity for
entrepreneurs to come together to share insights, development works and promote the best of entrepreneurial endeavor in
Maharashtra, India & world wide. So, Come, Nominate yourself and Be the Winner!

Awards Categories

General Awards
These are open to all entities having the requisite size, irrespective of the Industry Sector
they belong to.The intent is to recognize path breaking initiatives in the areas of Green /
Environment focus, CSR, Innovation and Emerging Businesses. An organization can
apply for multiple Award categories in the General category.

Industry Specific Awards Respecting Vision
We are looking for leading entities in the specific sectors contributing to the overall Honouring Actions
employment, investments and to the Economic Development of the State of Maharashtra
across Food and Food Processing, Pharmaceuticals and Biotech, Chemicals,
Automotive, Healthcare Services, IT/ITES, Financial Services, Public Infrastructure
development : Roads, Ports, Airports, etc., Infrastructure: Affordable Housing
Development, Industrial Parks, Renewable Energy, Engineering / Auto
Components.

Eligibility This Awards program is for companies that are headquartered in or have significant operations in the State of Maharashtra.
Criteria There are various Award categories for different sizes of companies and operating in specific industry sectors.

How to Apply? Assessment Criteria

The Awards Brochure and Entry Form can be obtained • Entrepreneurial spirit • Value Creation • Strategic Direction
through the following sources: • Regional, National and Global Impact • Innovation
• Personal Integrity/Purpose-driven Leadership
• The MEDC website: www.medcindia.com
• By emailing MEDC on [email protected]
• Contact MEDC office @ 022 22846288/2206

You Win & • Opportunity to showcase your achievements and contributions to the economy of Maharashtra
You Benefit! • Recognition of Winners at the prestigious Awards ceremony, in front of numerous

Government and Business dignitaries
• Publicity for Winners on MEDC website and various media partners of MEDC
• All participants get complimentary one-year MEDC membership

The Awards Function Award Partner
will be held in Mumbai
Scan QR Code to Scan QR Code to
Know about Know about region at the end of
Awards Guidelines August 2019, the date for
Categories & Rules
which will be
announced later

MAHARASHTRA ECONOMIC DEVELOPMENT COUNCIL
Y.B. Chavan Centre, 3rd floor,Nariman Point, Mumbai - 400 021 Tel : 2284 6288/ 2206/2209 Fax : 2284 6394

Email : [email protected] I Website : www.medcindia.com

50 BIO EVENT BIOSPECTRUM | JULY 2019 | www.biospectrumindia.com

PharmaLytica 2019 debuts in Mumbai

UBM India, the organisers (L to R) Pravin
of CPhI / P-MEC India, Mhapankar, President
the leading global pharma marketing, Thermolab;
trade show and conference, hosted Mayanki Gandhi, Senior
Research Scientist,
the 6th edition of PharmaLytica, IIT Mumbai; Shehul
Sheth, VP, Indian
for the first time in Mumbai, the Pharma Machinery
Manufacturer's
epicentre of the pharma hub, Association (IPMMA);
Yogesh Mudras,
especially in West India. The show Managing Director,
UBM India; Ritesh
was formerly held in Hyderabad. Modi, Director
Finance, UBM India
Organised at the Bombay at the inauguration of
PharmaLytica 2019 in
Exhibition Centre from 10-12 June Mumbai.

2019, the three day event was institution IIT Powai, Mumbai
exhibited its state-of-art Analytical
inaugurated in the presence of an Lab - the Sophisticated Analytical
Instrument Facility (SAIF). The
august industry gathering. facility was originally established at
the Indian Institute of Technology,
PharmaLytica enables the Machinery, Toshvin Analytical, Bombay, in the year 1976, with
Spinco Biotech, Scientific Research the support of the Department of
pharmaceutical community to Instruments, LP Global, Bitzer Science & Technology, Government
India and Anton Paar among of India, New Delhi. Besides, a
gather current industry trends, others. special three hour workshop on the
'Role & Commitment of GMP in
innovations and conduct business With country participation Pharma' by SGS Academy has been
from Luxembourg, United organised on Day 3 that would be
with Analytical, Laboratory, Kingdom, Germany and China, invaluable for pharma corporates
as well as state presence from attending the show.
Machinery, Ingredients, Packaging Maharashtra, Gujarat, Andhra
Pradesh, Telangana, Punjab, Speaking about the launch of
and other allied Industries. Haryana, Tamil Nadu, Delhi and the 6th edition of PharmaLytica
Uttarakhand, PharmaLytica is well in Hyderabad, Yogesh Mudras,
The expo is well supported on its way to becoming a truly pan- Managing Director, UBM India
India congregation that reaches said, "The Indian Pharma
by associations, including out to all major Industry sectors economy has been lauded for its
and pharma hubs. rapid growth in recent decades.
Pharmexcil, Confederation of As the much respected generics
This year's edition witnessed market in India has reached its
Indian Pharmaceutical Industry special pavilions dedicated to potential, the show provides
Pharma Machinery & Packaging; an ideal platform for pharma
(CiPi) and the Indian Drug Lab Analytical & Cleanroom and professionals to also ramp up the
API's & Excipients Pavilion. To ancillary section of the industry
Manufacturers’ Association enhance the touch-and-feel aspect to keep abreast with innovations
of the expo, one of the much- in the growing businesses of the
(IDMA). Starting this year, the anticipated highlights was the global pharma sector. Apart from
inclusion of Exhibitor Showcase, Pharma ingredients, increasingly,
reputed pharma related expo where visitors attended featured companies are looking at sub sectors
presentations, heard best of case such as Analytical & Bio Tech, Lab
seeks to leverage the opportunities studies around innovations and equipments & Lab Chemicals,
technologies trending within the Pharma Machinery and Packaging
provided by the impressive pharma Pharma marketplace. Exclusive with significant success."
B2B Meeting Area and Customer
hub in West India, while also being Insight Lounge was organised to
connect buyers and sellers, enhance
in close proximity to the South the ease of doing business as well
as to increase sectoral insights.
Indian market.
Among other notable
In the current edition, showcases, India's top academic

PharmaLytica witnessed the

participation of over 300 exhibitors

from across the country including

notable industry players, many of

whom are making their maiden

showcasing at PharmaLytica. Some

of the exhibitors include Elmach

Packages, Shimadzu, Dockweiler

AG, Micronclean, Rotarex, Bruker

India Scientific, Sartorius, Schott

Kaisha, Gattefosse, Perkin Elmer;

Thermolab Scientific Equipments,

Nicomac Cleanrooms, Mack

Pharmatech, Gangwal Chemicals,

Kirloskar Pneumatic, Swati

Spentose, Borosil Glass Works,

Accupack Engineering, NPM